<div id="content" filename="1" articleid="77142" rowid="77142" jrnlname="SPRINGER_AMA" style="height: 291.021px; right: -19px;" class="overthrow nano-content typesetter mce-content-body mce-edit-focus" data-hint-id="content" contenteditable="true" spellcheck="false" oncontextmenu="return false" tabindex="0"><div class="front" data-xpath="/div[1]"><p class="jrnlLRH" data-editable="true" data-xpath="/div[1]/p[1]"><span class="ins cts-1" title="Inserted by Bala (Springer Books) - 05/3/2016 12:31pm" data-cid="NaN" data-userid="5752" data-username="Bala (Springer Books)" data-time="1462258905544">V: ANTIEPILEPTIC DRUGS AND DIET</span></p><p class="jrnlRRH" data-editable="true" data-xpath="/div[1]/p[2]"><span class="ins cts-1" data-cid="2" data-userid="typesetter 5752" data-username="Bala (Springer Books)" data-time="1462258911350" title="Inserted by Bala (Springer Books) - 05/3/2016 12:31pm">69<span class="ins cts-2" data-cid="4" data-userid="copyeditor 4729" data-username=" (Springer Books)" data-time="1462788502577" title="Inserted by (Springer Books) - 05/9/2016 3:38pm">:</span><span class="del cts-2" data-cid="5" data-userid="copyeditor 4729" data-username=" (Springer Books)" data-time="1462788503762" title="Deleted by (Springer Books) - 05/9/2016 3:38pm">.</span>&nbsp;<span class="ins cts-1" title="Inserted by Bala (Springer Books) - 05/3/2016 12:31pm" data-cid="NaN" data-userid="5752" data-username="Bala (Springer Books)" data-time="1462258915098">DRUG DEVELOPMENT FOR EPILEPSY<span class="del cts-2" data-cid="6" data-userid="copyeditor 4729" data-username=" (Springer Books)" data-time="1462788510662" title="Deleted by (Springer Books) - 05/9/2016 3:38pm">: PAST, PRESENT AND FUTURE</span></span></span><br></p><h2 class="jrnlChapNumber" data-editable="true" data-xpath="/div[1]/h2[1]">CHAPTER 69</h2><h1 class="jrnlArtTitle" data-xpath="/div[1]/h1[1]" bold="true" data-editable="true">Drug Development for Epilepsy: Past, Present<span class="ins cts-2" data-cid="7" data-userid="copyeditor 4729" data-username=" (Springer Books)" data-time="1462789541334" title="Inserted by (Springer Books) - 05/9/2016 3:55pm">,</span> and Future</h1><p class="jrnlAuthors" data-xpath="/div[1]/p[3]" bold="true" data-editable="true"><span class="jrnlAuthor"><span class="jrnlGivenName">Edward</span> <span class="jrnlSurName">Chang</span></span> and <span class="jrnlAuthor"><span class="jrnlGivenName">Raman</span> <span class="jrnlSurName">Sankar</span></span></p></div><div class="body" data-xpath="/div[2]"><p class="jrnlSecPara" data-xpath="/div[2]/p[1]">This chapter <span class="del cts-2" data-cid="9" data-userid="copyeditor 4729" data-username=" (Springer Books)" data-time="1462789547339" title="Deleted by (Springer Books) - 05/9/2016 3:55pm">will </span>provide<span class="ins cts-2" data-cid="18" data-userid="copyeditor 4729" data-username=" (Springer Books)" data-time="1462789550792" title="Inserted by (Springer Books) - 05/9/2016 3:55pm">s</span> a bird’s eye view of anti<span class="del cts-2" data-cid="58" data-userid="copyeditor 4729" data-username=" (Springer Books)" data-time="1462790024543" title="Deleted by (Springer Books) - 05/9/2016 4:03pm">-</span>epileptic drug (AED) development from a historic perspective to discern major patterns in our thinking about this disease, which is in reality a collection of disorders that share seizures as a common symptom. The goal of therapeutics has expanded from immediate control of seizures<span class="del cts-2" data-cid="19" data-userid="copyeditor 4729" data-username=" (Springer Books)" data-time="1462789576526" title="Deleted by (Springer Books) - 05/9/2016 3:56pm">,</span> to a search for interventions that modify the course of the disease in the process. As our understanding grows, we can accommodate the concept that disease modification and acute seizure control may or may not coalesce in a single medication. The chapter <span class="del cts-2" data-cid="20" data-userid="copyeditor 4729" data-username=" (Springer Books)" data-time="1462789598426" title="Deleted by (Springer Books) - 05/9/2016 3:56pm">will </span>trace<span class="ins cts-2" data-cid="34" data-userid="copyeditor 4729" data-username=" (Springer Books)" data-time="1462789602105" title="Inserted by (Springer Books) - 05/9/2016 3:56pm">s</span> the evolution of our approach rather than duplicate readily available references such as the reports on the biennial Eilat conferences on AEDs under development (<span class="jrnlBibRef" data-type="ruleset" data-citation-string=" R1 ">1</span>), which contain details of the extent to which human clinical trials have progressed.</p><h1 class="jrnlHead1" align="center" data-xpath="/div[2]/h1[1]" bold="true" patternhead="true">FORCES THAT SHAPED AED DEVELOPMENT IN THE 19<span class="ins CTS-1" title="INSERTED BY BALA (SPRINGER BOOKS) - 05/3/2016 12:33PM" data-cid="16" data-userid="TYPESETTER 5752" data-username="BALA (SPRINGER BOOKS)" data-time="1462259035442">TH</span><sup fontsize="12.0PT"><span class="DEL CTS-1" title="DELETED BY BALA (SPRINGER BOOKS) - 05/3/2016 12:33PM" data-cid="18" data-userid="TYPESETTER 5752" data-username="BALA (SPRINGER BOOKS)" data-time="1462259036785"><span class="del" data-userid="5752" data-username="Bala (Springer Books)">TH</span></span></sup> AND 20<span class="ins CTS-1" title="INSERTED BY BALA (SPRINGER BOOKS) - 05/3/2016 12:34PM" data-cid="21" data-userid="TYPESETTER 5752" data-username="BALA (SPRINGER BOOKS)" data-time="1462259043701">TH</span><sup fontsize="12.0PT"><span class="DEL CTS-1" title="DELETED BY BALA (SPRINGER BOOKS) - 05/3/2016 12:34PM" data-cid="20" data-userid="TYPESETTER 5752" data-username="BALA (SPRINGER BOOKS)" data-time="1462259040790"><span class="del" data-userid="5752" data-username="Bala (Springer Books)">TH</span></span></sup> CENTURIES</h1><p class="jrnlSecPara" data-xpath="/div[2]/p[2]">The beginning of the era of “rational” medical treatment of epilepsy <span class="ins cts-2" data-cid="44" data-userid="copyeditor 4729" data-username=" (Springer Books)" data-time="1462789920009" title="Inserted by (Springer Books) - 05/9/2016 4:02pm">can be</span><span class="del cts-2" data-cid="35" data-userid="copyeditor 4729" data-username=" (Springer Books)" data-time="1462789914378" title="Deleted by (Springer Books) - 05/9/2016 4:01pm">is</span> traced to the use of potassium bromide by Sir Charles Locock to teat “hysterical epilepsy” in Victorian England (<span class="jrnlBibRef" data-type="ruleset" data-citation-string=" R2 ">2</span>). This was, indeed, the first effective therapy of epilepsy and was reported to the Royal Medical and Surgical Society in 1857. Bromide therapy was believed to be effective because of its ability to blunt libido<span class="ins cts-2" data-cid="50" data-userid="copyeditor 4729" data-username=" (Springer Books)" data-time="1462789947847" title="Inserted by (Springer Books) - 05/9/2016 4:02pm">,</span> <span class="ins cts-2" data-cid="51" data-userid="copyeditor 4729" data-username=" (Springer Books)" data-time="1462789950509" title="Inserted by (Springer Books) - 05/9/2016 4:02pm">as</span><span class="del cts-2" data-cid="53" data-userid="copyeditor 4729" data-username=" (Springer Books)" data-time="1462789951184" title="Deleted by (Springer Books) - 05/9/2016 4:02pm">since</span> the common prevailing view then was that excessive sexual indulgence, especially masturbation, gave rise to seizures and epilepsy, while hysteria was often <span class="authorQueryNode Author" id="1462789990279" rid="QRY_1462789990279" data-username=" (Springer Books)" data-time="05/9/2016 4:03pm">assigned to </span>women during menses. Despite incorrect reasoning, Sir Locock had succeeded in controlling what were likely catamenial seizures. Bromides were used for their sedative and antiaphrodisiac properties during that period. After the turn of the century, when barbiturates became available, the use of a sedative-hypnotic medication knowingly for the intended effect resulted in the identification of its anticonvulsant efficacy quite serendipitously. Phenobarbital had been administered mainly to sedate a ward of noisy epileptic patients in Freiburg during the night to enable Alfred Hauptman<span class="ins cts-2" data-cid="59" data-userid="copyeditor 4729" data-username=" (Springer Books)" data-time="1462790066207" title="Inserted by (Springer Books) - 05/9/2016 4:04pm">n</span>, the medical assistant (resident, in today’s parlance), to have a good night’s sleep. The observant Dr. Hauptman<span class="ins cts-2" data-cid="60" data-userid="copyeditor 4729" data-username=" (Springer Books)" data-time="1462790081779" title="Inserted by (Springer Books) - 05/9/2016 4:04pm">n</span> carefully recorded the decrement in seizures even during the day upon nightly administration of phenobarbital and described his findings in a seminal publication (<span class="jrnlBibRef" data-type="ruleset" data-citation-string=" R3 ">3</span>).</p><p class="jrnlSecPara" data-xpath="/div[2]/p[3]">From that point on, the increasing ability of chemists to tinker with the basic ring structure of phenobarbital, combined with new animal models of seizures, became the driving force behind the development of anticonvulsant drugs (<span class="jrnlFigRef" data-type="ruleset" data-citation-string=" F1 ">Figure <span class="ins cts-1" data-cid="3" data-userid="typesetter 5752" data-username="Bala (Springer Books)" data-time="1462266021019" title="Inserted by Bala (Springer Books) - 05/3/2016 2:30pm">69.</span>1</span>). Chemists got busy modifying the structure of phenobarbital<span class="del cts-2" data-cid="61" data-userid="copyeditor 4729" data-username=" (Springer Books)" data-time="1462790112724" title="Deleted by (Springer Books) - 05/9/2016 4:05pm">,</span> and noted that a simple change in the ring structure, removing one carbon<span class="ins cts-2" data-cid="62" data-userid="copyeditor 4729" data-username=" (Springer Books)" data-time="1462790121195" title="Inserted by (Springer Books) - 05/9/2016 4:05pm">&nbsp;atom</span>, resulted in the creation of hydantoins<span class="ins cts-2" data-cid="67" data-userid="copyeditor 4729" data-username=" (Springer Books)" data-time="1462790127855" title="Inserted by (Springer Books) - 05/9/2016 4:05pm">,</span> which displayed<span class="ins cts-2" data-cid="72" data-userid="copyeditor 4729" data-username=" (Springer Books)" data-time="1462790146074" title="Inserted by (Springer Books) - 05/9/2016 4:05pm">&nbsp;an</span> improved ratio of anti<span class="del cts-2" data-cid="77" data-userid="copyeditor 4729" data-username=" (Springer Books)" data-time="1462790155402" title="Deleted by (Springer Books) - 05/9/2016 4:05pm">-</span>seizure activity to sedation<span class="del cts-2" data-cid="78" data-userid="copyeditor 4729" data-username=" (Springer Books)" data-time="1462790161467" title="Deleted by (Springer Books) - 05/9/2016 4:06pm">,</span> or<span class="ins cts-2" data-cid="79" data-userid="copyeditor 4729" data-username=" (Springer Books)" data-time="1462790163999" title="Inserted by (Springer Books) - 05/9/2016 4:06pm">&nbsp;an</span> improved therapeutic index. The discovery of diphenylhydantoins, <span class="ins cts-2" data-cid="84" data-userid="copyeditor 4729" data-username=" (Springer Books)" data-time="1462790175107" title="Inserted by (Springer Books) - 05/9/2016 4:06pm">also known as</span><span class="del cts-2" data-cid="97" data-userid="copyeditor 4729" data-username=" (Springer Books)" data-time="1462790180248" title="Deleted by (Springer Books) - 05/9/2016 4:06pm">aka</span> phenytoin, in 1938 by Merritt and Putnam marked the era of applying medicinal chemistry to improve upon a serendipitous observation (<span class="jrnlBibRef" data-type="ruleset" data-citation-string=" R4 ">4</span>). Tracy Putnam had set up a laboratory at the Neurological Institute of Columbia University to test the ability of drugs to protect cats against electroshock seizures (<span class="jrnlBibRef" data-type="ruleset" data-citation-string=" R5 ">5</span>). Houston Merritt collaborated with Putnam in testing anti<span class="del cts-2" data-cid="100" data-userid="copyeditor 4729" data-username=" (Springer Books)" data-time="1462790224681" title="Deleted by (Springer Books) - 05/9/2016 4:07pm">-</span>seizure drugs in patients. <span class="ins cts-2" data-cid="101" data-userid="copyeditor 4729" data-username=" (Springer Books)" data-time="1462790237006" title="Inserted by (Springer Books) - 05/9/2016 4:07pm">The&nbsp;</span><span class="del cts-2" data-cid="107" data-userid="copyeditor 4729" data-username=" (Springer Books)" data-time="1462790243784" title="Deleted by (Springer Books) - 05/9/2016 4:07pm">S</span><span class="ins cts-2" data-cid="108" data-userid="copyeditor 4729" data-username=" (Springer Books)" data-time="1462790244359" title="Inserted by (Springer Books) - 05/9/2016 4:07pm">s</span>ubsequent identification that drugs that protected rodents against pentylenetetrazol (PTZ)-induced seizures were useful against absence seizures gave rise to the development of trimethadione, an oxazolidindione, as a specific agent for absence (then call<span class="ins cts-2" data-cid="109" data-userid="copyeditor 4729" data-username=" (Springer Books)" data-time="1462790267730" title="Inserted by (Springer Books) - 05/9/2016 4:07pm">ed</span> <span class="ins cts-4729" title="Inserted by (Springer Books) - 05/09/2016 4:08pm" data-cid="113" data-userid="4729" data-username=" (Springer Books)" data-time="1462790292962">“</span>petit mal<span class="ins cts-4729" title="Inserted by (Springer Books) - 05/09/2016 4:08pm" data-cid="114" data-userid="4729" data-username=" (Springer Books)" data-time="1462790302515">”</span>) seizures (<span class="jrnlBibRef" data-type="ruleset" data-citation-string=" R6 ">6</span>). Later, ethosuximide, shown in Figure <span class="ins cts-1" data-cid="8" data-userid="typesetter 5752" data-username="Bala (Springer Books)" data-time="1462266029392" title="Inserted by Bala (Springer Books) - 05/3/2016 2:30pm">69.</span>1, was found to be a safer agent against absence seizures. In the interest of space, we refer readers to two excellent sources for the fascinating story on the evolution of pharmacologic therapies in the second half the 20<span class="ins cts-1" data-cid="23" data-userid="typesetter 5752" data-username="Bala (Springer Books)" data-time="1462259072176" title="Inserted by Bala (Springer Books) - 05/3/2016 12:34pm">th</span><sup fontsize="12.0pt"><span class="del cts-1" data-cid="25" data-userid="typesetter 5752" data-username="Bala (Springer Books)" data-time="1462259073375" title="Deleted by Bala (Springer Books) - 05/3/2016 12:34pm">th</span></sup> century and the present era (<span class="jrnlBibRef" data-type="ruleset" data-citation-string=" R7 R8 ">7,8</span>).</p><p class="jrnlSecPara" data-xpath="/div[2]/p[4]" uc="true"><img width="516" height="231" id="Picture 1" src="/ecs/article/77142/resources/CH069_F001_BDS.jpg" data-xpath="/div[2]/p[4]/img[1]" data-mce-src="/ecs/article/77142/resources/CH069_F001_BDS.jpg" fontsize="12.0pt" data-primary-extension="eps" data-width="235" data-height="93" data-id="1648002" alt="ecs/article/77142/resources/CH069_F001_BDS.jpg"></p><p class="jrnlFigCaption" data-xpath="/div[2]/p[5]" id="F1"><b data-xpath="/p[11]/b[1]"><span class="label" data-type="ruleset">Figure <span class="ins cts-1" data-cid="11" data-userid="typesetter 5752" data-username="Bala (Springer Books)" data-time="1462266034554" title="Inserted by Bala (Springer Books) - 05/3/2016 2:30pm">69.</span>1<span class="del cts-1" data-cid="14" data-userid="typesetter 5752" data-username="Bala (Springer Books)" data-time="1462266036862" title="Deleted by Bala (Springer Books) - 05/3/2016 2:30pm">:</span></span></b><span class="ins cts-2" data-cid="116" data-userid="copyeditor 4729" data-username=" (Springer Books)" data-time="1462790395743" title="Inserted by (Springer Books) - 05/9/2016 4:09pm">&nbsp;<span class="authorQueryNode Author" id="1462790597935" rid="QRY_1462790597935" data-username=" (Springer Books)" data-time="05/9/2016 4:13pm">Structures of common anticonvulsant drugs.</span></span><span class="authorQueryNode Author" id="1462790597935" rid="QRY_1462790597935" data-username=" (Springer Books)" data-time="05/9/2016 4:13pm"> </span>The serendipitous discovery <span class="ins cts-2" data-cid="163" data-userid="copyeditor 4729" data-username=" (Springer Books)" data-time="1462790432418" title="Inserted by (Springer Books) - 05/9/2016 4:10pm">of the anticonvulsant efficacy of barbiturates&nbsp;</span>was followed by modifications to its basic structure. The arrows point to the elimination of the moiety from phenobarbital that led to the hydantoin ring structure<span class="ins cts-2" data-cid="210" data-userid="copyeditor 4729" data-username=" (Springer Books)" data-time="1462790463781" title="Inserted by (Springer Books) - 05/9/2016 4:11pm">.</span><span class="del cts-2" data-cid="211" data-userid="copyeditor 4729" data-username=" (Springer Books)" data-time="1462790465171" title="Deleted by (Springer Books) - 05/9/2016 4:11pm"> and</span> <span class="ins cts-2" data-cid="218" data-userid="copyeditor 4729" data-username=" (Springer Books)" data-time="1462790501322" title="Inserted by (Springer Books) - 05/9/2016 4:11pm">T</span><span class="del cts-2" data-cid="215" data-userid="copyeditor 4729" data-username=" (Springer Books)" data-time="1462790490503" title="Deleted by (Springer Books) - 05/9/2016 4:11pm">t</span>he substitution of a nitrogen atom in the hydantoin ring with carbon <span class="ins cts-2" data-cid="219" data-userid="copyeditor 4729" data-username=" (Springer Books)" data-time="1462790516273" title="Inserted by (Springer Books) - 05/9/2016 4:11pm">yielded</span><span class="del cts-2" data-cid="226" data-userid="copyeditor 4729" data-username=" (Springer Books)" data-time="1462790519364" title="Deleted by (Springer Books) - 05/9/2016 4:11pm">to produce</span> the succinimide drug ethosuximide.</p><p class="jrnlSecPara" data-xpath="/div[2]/p[6]">Since the second half of the 20<span class="ins cts-1" data-cid="27" data-userid="typesetter 5752" data-username="Bala (Springer Books)" data-time="1462259080654" title="Inserted by Bala (Springer Books) - 05/3/2016 12:34pm">th</span><sup fontsize="12.0pt"><span class="del cts-1" data-cid="29" data-userid="typesetter 5752" data-username="Bala (Springer Books)" data-time="1462259082011" title="Deleted by Bala (Springer Books) - 05/3/2016 12:34pm">th</span></sup> century, advances in neuroscience have <span class="ins cts-2" data-cid="236" data-userid="copyeditor 4729" data-username=" (Springer Books)" data-time="1462790619268" title="Inserted by (Springer Books) - 05/9/2016 4:13pm">led to the&nbsp;</span>evol<span class="ins cts-2" data-cid="253" data-userid="copyeditor 4729" data-username=" (Springer Books)" data-time="1462790629305" title="Inserted by (Springer Books) - 05/9/2016 4:13pm">ution</span><span class="del cts-2" data-cid="258" data-userid="copyeditor 4729" data-username=" (Springer Books)" data-time="1462790632454" title="Deleted by (Springer Books) - 05/9/2016 4:13pm">ved to pointing at</span> <span class="ins cts-2" data-cid="276" data-userid="copyeditor 4729" data-username=" (Springer Books)" data-time="1462790671616" title="Inserted by (Springer Books) - 05/9/2016 4:14pm">of&nbsp;</span>numerous molecular targets (generally ion channels) <span class="ins cts-2" data-cid="279" data-userid="copyeditor 4729" data-username=" (Springer Books)" data-time="1462790679202" title="Inserted by (Springer Books) - 05/9/2016 4:14pm">capable of</span><span class="del cts-2" data-cid="291" data-userid="copyeditor 4729" data-username=" (Springer Books)" data-time="1462790685231" title="Deleted by (Springer Books) - 05/9/2016 4:14pm">relevant to</span> modifying neuronal excitability, <span class="ins cts-2" data-cid="302" data-userid="copyeditor 4729" data-username=" (Springer Books)" data-time="1462790726646" title="Inserted by (Springer Books) - 05/9/2016 4:15pm">which in turn has</span><span class="del cts-2" data-cid="319" data-userid="copyeditor 4729" data-username=" (Springer Books)" data-time="1462790742240" title="Deleted by (Springer Books) - 05/9/2016 4:15pm">and have come to</span> influence<span class="ins cts-2" data-cid="335" data-userid="copyeditor 4729" data-username=" (Springer Books)" data-time="1462790757737" title="Inserted by (Springer Books) - 05/9/2016 4:15pm">d</span> the development of <span class="del cts-2" data-cid="336" data-userid="copyeditor 4729" data-username=" (Springer Books)" data-time="1462790763928" title="Deleted by (Springer Books) - 05/9/2016 4:16pm">the development of </span>AEDs. Chapters 2 and 3 in <span class="del cts-2" data-cid="355" data-userid="copyeditor 4729" data-username=" (Springer Books)" data-time="1462790780069" title="Deleted by (Springer Books) - 05/9/2016 4:16pm">the first s</span><span class="ins cts-2" data-cid="366" data-userid="copyeditor 4729" data-username=" (Springer Books)" data-time="1462790785592" title="Inserted by (Springer Books) - 05/9/2016 4:16pm">S</span>ection<span class="ins cts-2" data-cid="367" data-userid="copyeditor 4729" data-username=" (Springer Books)" data-time="1462790792796" title="Inserted by (Springer Books) - 05/9/2016 4:16pm">&nbsp;I</span> of this book and Chapter 40 in <span class="del cts-2" data-cid="369" data-userid="copyeditor 4729" data-username=" (Springer Books)" data-time="1462790803237" title="Deleted by (Springer Books) - 05/9/2016 4:16pm">s</span><span class="ins cts-2" data-cid="370" data-userid="copyeditor 4729" data-username=" (Springer Books)" data-time="1462790803926" title="Inserted by (Springer Books) - 05/9/2016 4:16pm">S</span>ection <span class="ins cts-2" data-cid="371" data-userid="copyeditor 4729" data-username=" (Springer Books)" data-time="1462790806627" title="Inserted by (Springer Books) - 05/9/2016 4:16pm">IV</span><span class="del cts-2" data-cid="373" data-userid="copyeditor 4729" data-username=" (Springer Books)" data-time="1462790807972" title="Deleted by (Springer Books) - 05/9/2016 4:16pm">4</span> are useful sources to review the details <span class="ins cts-2" data-cid="374" data-userid="copyeditor 4729" data-username=" (Springer Books)" data-time="1462790824433" title="Inserted by (Springer Books) - 05/9/2016 4:17pm">of</span><span class="del cts-2" data-cid="376" data-userid="copyeditor 4729" data-username=" (Springer Books)" data-time="1462790825139" title="Deleted by (Springer Books) - 05/9/2016 4:17pm">about</span> these mechanisms. The discovery that classic AEDs<span class="ins cts-2" data-cid="381" data-userid="copyeditor 4729" data-username=" (Springer Books)" data-time="1462790894602" title="Inserted by (Springer Books) - 05/9/2016 4:18pm">, which were</span> developed as a result of their success in the maximal electroshock model<span class="ins cts-2" data-cid="393" data-userid="copyeditor 4729" data-username=" (Springer Books)" data-time="1462790908943" title="Inserted by (Springer Books) - 05/9/2016 4:18pm">,</span> <span class="ins cts-2" data-cid="394" data-userid="copyeditor 4729" data-username=" (Springer Books)" data-time="1462790916001" title="Inserted by (Springer Books) - 05/9/2016 4:18pm">were</span><span class="del cts-2" data-cid="400" data-userid="copyeditor 4729" data-username=" (Springer Books)" data-time="1462790920094" title="Deleted by (Springer Books) - 05/9/2016 4:18pm">turned out to be</span> inhibitors of voltage-gated sodium channels (VGSC<span class="ins cts-2" data-cid="416" data-userid="copyeditor 4729" data-username=" (Springer Books)" data-time="1462790933373" title="Inserted by (Springer Books) - 05/9/2016 4:18pm">s</span>) was followed by the demonstration that drugs developed by the PTZ<span class="ins cts-2" data-cid="417" data-userid="copyeditor 4729" data-username=" (Springer Books)" data-time="1462790950646" title="Inserted by (Springer Books) - 05/9/2016 4:19pm">&nbsp;</span><span class="del cts-2" data-cid="418" data-userid="copyeditor 4729" data-username=" (Springer Books)" data-time="1462790951053" title="Deleted by (Springer Books) - 05/9/2016 4:19pm">-</span>model were capable of inhibiting low-threshold or T-calcium channels. These two models formed the “archetypes” for the development of AEDs for partial (<span class="ins cts-4729" title="Inserted by (Springer Books) - 05/09/2016 4:19pm" data-cid="421" data-userid="4729" data-username=" (Springer Books)" data-time="1462790970970">“</span>focal<span class="ins cts-4729" title="Inserted by (Springer Books) - 05/09/2016 4:20pm" data-cid="424" data-userid="4729" data-username=" (Springer Books)" data-time="1462791012856">”</span> in new terminology) and secondarily generalized seizures typified by phenytoin versus those <span class="ins cts-2" data-cid="425" data-userid="copyeditor 4729" data-username=" (Springer Books)" data-time="1462791030090" title="Inserted by (Springer Books) - 05/9/2016 4:20pm">that are&nbsp;</span>active against the primary generalized seizures typified by trimethadione and ethosuximide (<span class="jrnlBibRef" data-type="ruleset" data-citation-string=" R9 ">9</span>). Other approaches to limiting excitatory currents have involved compound<span class="ins cts-2" data-cid="434" data-userid="copyeditor 4729" data-username=" (Springer Books)" data-time="1462791077744" title="Inserted by (Springer Books) - 05/9/2016 4:21pm">s</span> that act on glutamatergic currents<span class="ins cts-4729" title="Inserted by (Springer Books) - 05/09/2016 4:21pm" data-cid="435" data-userid="4729" data-username=" (Springer Books)" data-time="1462791089351">—<span class="del cts-2" data-cid="436" data-userid="copyeditor 4729" data-username=" (Springer Books)" data-time="1462791094180" title="Deleted by (Springer Books) - 05/9/2016 4:21pm"> </span></span><span class="del cts-2" data-cid="437" data-userid="copyeditor 4729" data-username=" (Springer Books)" data-time="1462791095001" title="Deleted by (Springer Books) - 05/9/2016 4:21pm"> – </span>felbamate was found to antagonize <span class="ins cts-2" data-cid="440" data-userid="copyeditor 4729" data-username=" (Springer Books)" data-time="1462791110617" title="Inserted by (Springer Books) - 05/9/2016 4:21pm"><em>N</em>-methyl-<span class="authorQueryNode Typesetter" id="1462791262671" rid="QRY_1462791262671" data-username=" (Springer Books)" data-time="05/9/2016 4:24pm">d</span><span class="authorQueryNode Typesetter" id="1462791262671" rid="QRY_1462791262671" data-username=" (Springer Books)" data-time="05/9/2016 4:24pm">-</span>aspartate (</span>NMDA<span class="ins cts-2" data-cid="464" data-userid="copyeditor 4729" data-username=" (Springer Books)" data-time="1462791143160" title="Inserted by (Springer Books) - 05/9/2016 4:22pm">)</span>-mediated Ca<sup fontsize="12.0pt"><span class="del cts-2" data-cid="465" data-userid="copyeditor 4729" data-username=" (Springer Books)" data-time="1462791147233" title="Deleted by (Springer Books) - 05/9/2016 4:22pm">+</span><span class="ins cts-2" data-cid="466" data-userid="copyeditor 4729" data-username=" (Springer Books)" data-time="1462791147641" title="Inserted by (Springer Books) - 05/9/2016 4:22pm">2</span>+</sup> currents (<span class="jrnlBibRef" data-type="ruleset" data-citation-string=" R10 ">10</span>)<span class="ins cts-2" data-cid="469" data-userid="copyeditor 4729" data-username=" (Springer Books)" data-time="1462791296212" title="Inserted by (Springer Books) - 05/9/2016 4:24pm">,</span> while the newer agent perampanel antagonizes <span class="ins cts-1" title="Inserted by (Springer Books) - 05/9/2016 4:25pm" data-cid="NaN" data-userid="4729" data-username=" (Springer Books)" data-time="1462791332388">alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (</span>AMPA<span class="ins cts-2" data-cid="470" data-userid="copyeditor 4729" data-username=" (Springer Books)" data-time="1462791337296" title="Inserted by (Springer Books) - 05/9/2016 4:25pm">)</span>-mediated Na<sup fontsize="12.0pt">+</sup> currents (<span class="jrnlBibRef" data-type="ruleset" data-citation-string=" R11 ">11</span>). Likewise<span class="ins cts-2" data-cid="471" data-userid="copyeditor 4729" data-username=" (Springer Books)" data-time="1462791347297" title="Inserted by (Springer Books) - 05/9/2016 4:25pm">,</span> the discovery that phenobarbital and benzodiazepines augmented inhibition by enhancing <span class="ins cts-1" title="Inserted by (Springer Books) - 05/9/2016 4:26pm" data-cid="NaN" data-userid="4729" data-username=" (Springer Books)" data-time="1462791378489">gamma-aminobutyric acid</span><span class="ins cts-1" title="Inserted by (Springer Books) - 05/9/2016 4:26pm" data-cid="NaN" data-userid="4729" data-username=" (Springer Books)" data-time="1462791378489"> (</span>GABA<span class="ins cts-2" data-cid="472" data-userid="copyeditor 4729" data-username=" (Springer Books)" data-time="1462791381759" title="Inserted by (Springer Books) - 05/9/2016 4:26pm">)</span>-mediated Cl<sup><span class="ins cts-4729" title="Inserted by (Springer Books) - 05/09/2016 4:27pm" data-cid="473" data-userid="4729" data-username=" (Springer Books)" data-time="1462791443257">-</span></sup><sup fontsize="12.0pt"><span class="del cts-2" data-cid="474" data-userid="copyeditor 4729" data-username=" (Springer Books)" data-time="1462791459110" title="Deleted by (Springer Books) - 05/9/2016 4:27pm">-</span></sup> currents as a result of their binding to allosteric sites on the GABA receptor (<span class="jrnlBibRef" data-type="ruleset" data-citation-string=" R12 ">12</span>). <span class="ins cts-2" data-cid="480" data-userid="copyeditor 4729" data-username=" (Springer Books)" data-time="1462791488264" title="Inserted by (Springer Books) - 05/9/2016 4:28pm"><span class="authorQueryNode Author" id="1462791741002" rid="QRY_1462791741002" data-username=" (Springer Books)" data-time="05/9/2016 4:32pm">Until</span></span><span class="del cts-2" data-cid="475" data-userid="copyeditor 4729" data-username=" (Springer Books)" data-time="1462791482715" title="Deleted by (Springer Books) - 05/9/2016 4:28pm"><span class="authorQueryNode Author" id="1462791741002" rid="QRY_1462791741002" data-username=" (Springer Books)" data-time="05/9/2016 4:32pm">U</span><span class="authorQueryNode Author" id="1462791741002" rid="QRY_1462791741002" data-username=" (Springer Books)" data-time="05/9/2016 4:32pm">p</span><span class="authorQueryNode Author" id="1462791741002" rid="QRY_1462791741002" data-username=" (Springer Books)" data-time="05/9/2016 4:32pm"> </span><span class="authorQueryNode Author" id="1462791741002" rid="QRY_1462791741002" data-username=" (Springer Books)" data-time="05/9/2016 4:32pm">t</span><span class="authorQueryNode Author" id="1462791741002" rid="QRY_1462791741002" data-username=" (Springer Books)" data-time="05/9/2016 4:32pm">o</span></span><span class="authorQueryNode Author" id="1462791741002" rid="QRY_1462791741002" data-username=" (Springer Books)" data-time="05/9/2016 4:32pm"> this point, and even beyond, AEDs were screened </span><span class="ins cts-2" data-cid="485" data-userid="copyeditor 4729" data-username=" (Springer Books)" data-time="1462791498036" title="Inserted by (Springer Books) - 05/9/2016 4:28pm"><span class="authorQueryNode Author" id="1462791741002" rid="QRY_1462791741002" data-username=" (Springer Books)" data-time="05/9/2016 4:32pm">using</span></span><span class="del cts-2" data-cid="490" data-userid="copyeditor 4729" data-username=" (Springer Books)" data-time="1462791499702" title="Deleted by (Springer Books) - 05/9/2016 4:28pm"><span class="authorQueryNode Author" id="1462791741002" rid="QRY_1462791741002" data-username=" (Springer Books)" data-time="05/9/2016 4:32pm">w</span><span class="authorQueryNode Author" id="1462791741002" rid="QRY_1462791741002" data-username=" (Springer Books)" data-time="05/9/2016 4:32pm">i</span><span class="authorQueryNode Author" id="1462791741002" rid="QRY_1462791741002" data-username=" (Springer Books)" data-time="05/9/2016 4:32pm">t</span><span class="authorQueryNode Author" id="1462791741002" rid="QRY_1462791741002" data-username=" (Springer Books)" data-time="05/9/2016 4:32pm">h</span></span><span class="authorQueryNode Author" id="1462791741002" rid="QRY_1462791741002" data-username=" (Springer Books)" data-time="05/9/2016 4:32pm"> animal models</span><span class="del cts-2" data-cid="494" data-userid="copyeditor 4729" data-username=" (Springer Books)" data-time="1462791510651" title="Deleted by (Springer Books) - 05/9/2016 4:28pm"><span class="authorQueryNode Author" id="1462791741002" rid="QRY_1462791741002" data-username=" (Springer Books)" data-time="05/9/2016 4:32pm">,</span></span><span class="authorQueryNode Author" id="1462791741002" rid="QRY_1462791741002" data-username=" (Springer Books)" data-time="05/9/2016 4:32pm"> </span><span class="ins cts-2" data-cid="495" data-userid="copyeditor 4729" data-username=" (Springer Books)" data-time="1462791513910" title="Inserted by (Springer Books) - 05/9/2016 4:28pm"><span class="authorQueryNode Author" id="1462791741002" rid="QRY_1462791741002" data-username=" (Springer Books)" data-time="05/9/2016 4:32pm">and were bring used in clinical settings</span></span><span class="del cts-2" data-cid="535" data-userid="copyeditor 4729" data-username=" (Springer Books)" data-time="1462791527550" title="Deleted by (Springer Books) - 05/9/2016 4:28pm"><span class="authorQueryNode Author" id="1462791741002" rid="QRY_1462791741002" data-username=" (Springer Books)" data-time="05/9/2016 4:32pm">c</span><span class="authorQueryNode Author" id="1462791741002" rid="QRY_1462791741002" data-username=" (Springer Books)" data-time="05/9/2016 4:32pm">a</span><span class="authorQueryNode Author" id="1462791741002" rid="QRY_1462791741002" data-username=" (Springer Books)" data-time="05/9/2016 4:32pm">m</span><span class="authorQueryNode Author" id="1462791741002" rid="QRY_1462791741002" data-username=" (Springer Books)" data-time="05/9/2016 4:32pm">e</span><span class="authorQueryNode Author" id="1462791741002" rid="QRY_1462791741002" data-username=" (Springer Books)" data-time="05/9/2016 4:32pm"> </span><span class="authorQueryNode Author" id="1462791741002" rid="QRY_1462791741002" data-username=" (Springer Books)" data-time="05/9/2016 4:32pm">i</span><span class="authorQueryNode Author" id="1462791741002" rid="QRY_1462791741002" data-username=" (Springer Books)" data-time="05/9/2016 4:32pm">n</span><span class="authorQueryNode Author" id="1462791741002" rid="QRY_1462791741002" data-username=" (Springer Books)" data-time="05/9/2016 4:32pm">t</span><span class="authorQueryNode Author" id="1462791741002" rid="QRY_1462791741002" data-username=" (Springer Books)" data-time="05/9/2016 4:32pm">o</span><span class="authorQueryNode Author" id="1462791741002" rid="QRY_1462791741002" data-username=" (Springer Books)" data-time="05/9/2016 4:32pm"> </span><span class="authorQueryNode Author" id="1462791741002" rid="QRY_1462791741002" data-username=" (Springer Books)" data-time="05/9/2016 4:32pm">c</span><span class="authorQueryNode Author" id="1462791741002" rid="QRY_1462791741002" data-username=" (Springer Books)" data-time="05/9/2016 4:32pm">l</span><span class="authorQueryNode Author" id="1462791741002" rid="QRY_1462791741002" data-username=" (Springer Books)" data-time="05/9/2016 4:32pm">i</span><span class="authorQueryNode Author" id="1462791741002" rid="QRY_1462791741002" data-username=" (Springer Books)" data-time="05/9/2016 4:32pm">n</span><span class="authorQueryNode Author" id="1462791741002" rid="QRY_1462791741002" data-username=" (Springer Books)" data-time="05/9/2016 4:32pm">i</span><span class="authorQueryNode Author" id="1462791741002" rid="QRY_1462791741002" data-username=" (Springer Books)" data-time="05/9/2016 4:32pm">c</span><span class="authorQueryNode Author" id="1462791741002" rid="QRY_1462791741002" data-username=" (Springer Books)" data-time="05/9/2016 4:32pm">a</span><span class="authorQueryNode Author" id="1462791741002" rid="QRY_1462791741002" data-username=" (Springer Books)" data-time="05/9/2016 4:32pm">l</span><span class="authorQueryNode Author" id="1462791741002" rid="QRY_1462791741002" data-username=" (Springer Books)" data-time="05/9/2016 4:32pm"> </span><span class="authorQueryNode Author" id="1462791741002" rid="QRY_1462791741002" data-username=" (Springer Books)" data-time="05/9/2016 4:32pm">u</span><span class="authorQueryNode Author" id="1462791741002" rid="QRY_1462791741002" data-username=" (Springer Books)" data-time="05/9/2016 4:32pm">s</span><span class="authorQueryNode Author" id="1462791741002" rid="QRY_1462791741002" data-username=" (Springer Books)" data-time="05/9/2016 4:32pm">e</span></span><span class="authorQueryNode Author" id="1462791741002" rid="QRY_1462791741002" data-username=" (Springer Books)" data-time="05/9/2016 4:32pm">, </span><span class="ins cts-2" data-cid="557" data-userid="copyeditor 4729" data-username=" (Springer Books)" data-time="1462791547892" title="Inserted by (Springer Books) - 05/9/2016 4:29pm"><span class="authorQueryNode Author" id="1462791741002" rid="QRY_1462791741002" data-username=" (Springer Books)" data-time="05/9/2016 4:32pm">but</span></span><span class="del cts-2" data-cid="560" data-userid="copyeditor 4729" data-username=" (Springer Books)" data-time="1462791548759" title="Deleted by (Springer Books) - 05/9/2016 4:29pm"><span class="authorQueryNode Author" id="1462791741002" rid="QRY_1462791741002" data-username=" (Springer Books)" data-time="05/9/2016 4:32pm">a</span><span class="authorQueryNode Author" id="1462791741002" rid="QRY_1462791741002" data-username=" (Springer Books)" data-time="05/9/2016 4:32pm">n</span><span class="authorQueryNode Author" id="1462791741002" rid="QRY_1462791741002" data-username=" (Springer Books)" data-time="05/9/2016 4:32pm">d</span></span><span class="authorQueryNode Author" id="1462791741002" rid="QRY_1462791741002" data-username=" (Springer Books)" data-time="05/9/2016 4:32pm"> the mechanisms of action of </span><span class="ins cts-2" data-cid="563" data-userid="copyeditor 4729" data-username=" (Springer Books)" data-time="1462791557906" title="Inserted by (Springer Books) - 05/9/2016 4:29pm"><span class="authorQueryNode Author" id="1462791741002" rid="QRY_1462791741002" data-username=" (Springer Books)" data-time="05/9/2016 4:32pm">these</span></span><span class="del cts-2" data-cid="568" data-userid="copyeditor 4729" data-username=" (Springer Books)" data-time="1462791559664" title="Deleted by (Springer Books) - 05/9/2016 4:29pm"><span class="authorQueryNode Author" id="1462791741002" rid="QRY_1462791741002" data-username=" (Springer Books)" data-time="05/9/2016 4:32pm">t</span><span class="authorQueryNode Author" id="1462791741002" rid="QRY_1462791741002" data-username=" (Springer Books)" data-time="05/9/2016 4:32pm">h</span><span class="authorQueryNode Author" id="1462791741002" rid="QRY_1462791741002" data-username=" (Springer Books)" data-time="05/9/2016 4:32pm">o</span><span class="authorQueryNode Author" id="1462791741002" rid="QRY_1462791741002" data-username=" (Springer Books)" data-time="05/9/2016 4:32pm">s</span><span class="authorQueryNode Author" id="1462791741002" rid="QRY_1462791741002" data-username=" (Springer Books)" data-time="05/9/2016 4:32pm">e</span></span><span class="authorQueryNode Author" id="1462791741002" rid="QRY_1462791741002" data-username=" (Springer Books)" data-time="05/9/2016 4:32pm"> AEDs were unraveled after the fact.</span> However, <span class="ins cts-2" data-cid="573" data-userid="copyeditor 4729" data-username=" (Springer Books)" data-time="1462791588589" title="Inserted by (Springer Books) - 05/9/2016 4:29pm">this</span><span class="del cts-2" data-cid="577" data-userid="copyeditor 4729" data-username=" (Springer Books)" data-time="1462791591533" title="Deleted by (Springer Books) - 05/9/2016 4:29pm">these</span> basic understanding<span class="del cts-2" data-cid="582" data-userid="copyeditor 4729" data-username=" (Springer Books)" data-time="1462791597429" title="Deleted by (Springer Books) - 05/9/2016 4:29pm">s</span> led to the prospective evaluation of drugs affecting processes <span class="ins cts-2" data-cid="583" data-userid="copyeditor 4729" data-username=" (Springer Books)" data-time="1462794008296" title="Inserted by (Springer Books) - 05/9/2016 5:10pm">that are&nbsp;</span>highly related to the modification of neuronal excitability by influencing neurotransmitter synthesis, storage, release, reuptake, and metabolism. That is the story of the evolution of vigabatrin (<span class="ins cts-2" data-cid="592" data-userid="copyeditor 4729" data-username=" (Springer Books)" data-time="1462794034999" title="Inserted by (Springer Books) - 05/9/2016 5:10pm">gamma</span><span class="del cts-2" data-cid="597" data-userid="copyeditor 4729" data-username=" (Springer Books)" data-time="1462794037279" title="Deleted by (Springer Books) - 05/9/2016 5:10pm">?</span>-vinyl GABA<span class="del cts-2" data-cid="598" data-userid="copyeditor 4729" data-username=" (Springer Books)" data-time="1462794042696" title="Deleted by (Springer Books) - 05/9/2016 5:10pm">,</span> <span class="ins cts-2" data-cid="599" data-userid="copyeditor 4729" data-username=" (Springer Books)" data-time="1462794045230" title="Inserted by (Springer Books) - 05/9/2016 5:10pm">[</span>GVG<span class="ins cts-2" data-cid="600" data-userid="copyeditor 4729" data-username=" (Springer Books)" data-time="1462794047332" title="Inserted by (Springer Books) - 05/9/2016 5:10pm">]</span>), a suicide substrate of GABA-transaminase (<span class="jrnlBibRef" data-type="ruleset" data-citation-string=" R13 ">13</span>) and tiagabine, a nipecotic acid derivative that blocks the reuptake of GABA (<span class="jrnlBibRef" data-type="ruleset" data-citation-string=" R14 ">14</span>). Other mechanisms such as the modification of the high-voltage Ca<sup fontsize="12.0pt"><span class="del cts-2" data-cid="601" data-userid="copyeditor 4729" data-username=" (Springer Books)" data-time="1462795335989" title="Deleted by (Springer Books) - 05/9/2016 5:32pm">+</span><span class="ins cts-2" data-cid="602" data-userid="copyeditor 4729" data-username=" (Springer Books)" data-time="1462795336377" title="Inserted by (Springer Books) - 05/9/2016 5:32pm">2</span>+</sup> currents in the presynaptic terminal by binding of gabapentin to the extracellular <span class="authorQueryNode Author" id="1462795403043" rid="QRY_1462795403043" data-username=" (Springer Books)" data-time="05/9/2016 5:33pm">a-2-d </span>loop of the P/Q type channels (<span class="jrnlBibRef" data-type="ruleset" data-citation-string=" R15 ">15</span>) or the binding of levetiracetam to the synaptic vesicle protein SV2A (<span class="jrnlBibRef" data-type="ruleset" data-citation-string=" R16 ">16</span>) were discovered after <span class="ins cts-2" data-cid="603" data-userid="copyeditor 4729" data-username=" (Springer Books)" data-time="1462795426232" title="Inserted by (Springer Books) - 05/9/2016 5:33pm">these</span><span class="del cts-2" data-cid="608" data-userid="copyeditor 4729" data-username=" (Springer Books)" data-time="1462795427849" title="Deleted by (Springer Books) - 05/9/2016 5:33pm">those</span> AEDs were already in use. In parallel, newer models for screening compounds for activity against seizures, especially seizures refractory to already existing AEDs, were developed (<span class="jrnlBibRef" data-type="ruleset" data-citation-string=" R17 R18 R19 R20 R21 R22 ">17<span class="del cts-5752" title="Inserted by Bala (Springer Books) - 05/03/2016 2:43pm" data-cid="37" data-userid="5752" data-username="Bala (Springer Books)" data-time="1462266833882">-</span><span class="ins cts-5752" title="Inserted by Bala (Springer Books) - 05/03/2016 2:43pm" data-cid="38" data-userid="5752" data-username="Bala (Springer Books)" data-time="1462266833887">–</span>22</span>). These have included rats resistant to specific AEDs such as phenytoin, phenobarbital<span class="ins cts-2" data-cid="613" data-userid="copyeditor 4729" data-username=" (Springer Books)" data-time="1462795449990" title="Inserted by (Springer Books) - 05/9/2016 5:34pm">,</span> or lamotrigine (<span class="jrnlBibRef" data-type="ruleset" data-citation-string=" R19 R20 R21 ">19<span class="del cts-5752" title="Inserted by Bala (Springer Books) - 05/03/2016 2:44pm" data-cid="39" data-userid="5752" data-username="Bala (Springer Books)" data-time="1462266852085">-</span><span class="ins cts-5752" title="Inserted by Bala (Springer Books) - 05/03/2016 2:44pm" data-cid="40" data-userid="5752" data-username="Bala (Springer Books)" data-time="1462266852090">–</span>21</span>) as well as the 6-Hz stimulation model that is being widely adopted in AED development (<span class="jrnlBibRef" data-type="ruleset" data-citation-string=" R22 ">22</span>).</p><p class="jrnlSecPara" data-xpath="/div[2]/p[7]">What is interesting to note is that when AEDs were designed with a certain type of mechanism in mind, they did not consistently turn out to actually display that property or succeed therapeutically. Thus<span class="ins cts-2" data-cid="614" data-userid="copyeditor 4729" data-username=" (Springer Books)" data-time="1462795493079" title="Inserted by (Springer Books) - 05/9/2016 5:34pm">,</span> gabapentin did not turn out to be a GABAergic agonist, and the GABA-prodrug progabide did not survive clinical trials (<span class="jrnlBibRef" data-type="ruleset" data-citation-string=" R23 R24 ">23, 24</span>). <span class="del cts-2" data-cid="615" data-userid="copyeditor 4729" data-username=" (Springer Books)" data-time="1462795583653" title="Deleted by (Springer Books) - 05/9/2016 5:36pm">And t</span><span class="ins cts-2" data-cid="620" data-userid="copyeditor 4729" data-username=" (Springer Books)" data-time="1462795587520" title="Inserted by (Springer Books) - 05/9/2016 5:36pm">T</span>he exact mechanism of action of valproic acid remains unclear <span class="ins cts-2" data-cid="626" data-userid="copyeditor 4729" data-username=" (Springer Books)" data-time="1462795600226" title="Inserted by (Springer Books) - 05/9/2016 5:36pm">as</span><span class="del cts-2" data-cid="621" data-userid="copyeditor 4729" data-username=" (Springer Books)" data-time="1462795595191" title="Deleted by (Springer Books) - 05/9/2016 5:36pm">since</span> many of the effects observed in vitro are seen at higher concentrations than are achieved in clinical use. Further, many AEDs display multiple mechanisms of action, and we may not know all the mechanisms for many.</p><p class="jrnlSecPara" data-xpath="/div[2]/p[8]"><span class="jrnlStyledContent" data-background-color="#FFFFFF" style="background-color: #ffffff;" data-mce-style="background-color: #ffffff;">Another successful </span>approach has involved leveraging the identified target, <span class="del cts-2" data-cid="628" data-userid="copyeditor 4729" data-username=" (Springer Books)" data-time="1462797108792" title="Deleted by (Springer Books) - 05/9/2016 6:01pm">and </span>going back to the laboratory to synthesize a large number of analogs<span class="ins cts-2" data-cid="632" data-userid="copyeditor 4729" data-username=" (Springer Books)" data-time="1462797114609" title="Inserted by (Springer Books) - 05/9/2016 6:01pm">,</span> and optimizing the structure based on interaction with that specific target in vitro, and then sequentially moving to animal models (including the new models such the 6-Hz stimulation model to mimic refractory focal dyscognitive seizures) and systematic clinical trials, as shown <span class="del cts-2" data-cid="660" data-userid="copyeditor 4729" data-username=" (Springer Books)" data-time="1462797393565" title="Deleted by (Springer Books) - 05/9/2016 6:06pm">in the schema </span>in Figure <span class="ins cts-1" data-cid="15" data-userid="typesetter 5752" data-username="Bala (Springer Books)" data-time="1462266043794" title="Inserted by Bala (Springer Books) - 05/3/2016 2:30pm">69.</span>2<span class="del cts-2" data-cid="633" data-userid="copyeditor 4729" data-username=" (Springer Books)" data-time="1462797158259" title="Deleted by (Springer Books) - 05/9/2016 6:02pm"> below</span>. This is the story of the development of brivaracetam, which shows much higher affinity toward<span class="del cts-2" data-cid="661" data-userid="copyeditor 4729" data-username=" (Springer Books)" data-time="1462797405508" title="Deleted by (Springer Books) - 05/9/2016 6:06pm">s</span> the SV2A binding site than levetiracetam, and no discernible binding to other sites at relevant concentrations (<span class="jrnlBibRef" data-type="ruleset" data-citation-string=" R25 ">25</span>).</p><p class="jrnlSecPara" data-xpath="/div[2]/p[9]">The approach of molecular optimization <span class="ins cts-2" data-cid="664" data-userid="copyeditor 4729" data-username=" (Springer Books)" data-time="1462797447237" title="Inserted by (Springer Books) - 05/9/2016 6:07pm">in</span><span class="del cts-2" data-cid="662" data-userid="copyeditor 4729" data-username=" (Springer Books)" data-time="1462797443693" title="Deleted by (Springer Books) - 05/9/2016 6:07pm">by</span> medicinal chemistry continues to offer interesting opportunities for new AED development. A sterically rigid analog of vigabatrin, incorporating the structure of <span class="ins cts-2" data-cid="643" data-userid="copyeditor 4729" data-username=" (Springer Books)" data-time="1462797343190" title="Inserted by (Springer Books) - 05/9/2016 6:05pm">GVG</span><span class="del cts-2" data-cid="646" data-userid="copyeditor 4729" data-username=" (Springer Books)" data-time="1462797345885" title="Deleted by (Springer Books) - 05/9/2016 6:05pm">?-vinyl GABA</span> in a cyclopentane ring ((1S,3S)-3-amino-4-difluoromethylenyl-1-cyclopentanoic acid) called CPP-115 has been synthesized (<span class="jrnlBibRef" data-type="ruleset" data-citation-string=" R26 ">26</span>), which appears to be approximately 200<span class="ins cts-2" data-cid="659" data-userid="copyeditor 4729" data-username=" (Springer Books)" data-time="1462797370892" title="Inserted by (Springer Books) - 05/9/2016 6:06pm">&nbsp;</span><span class="del cts-2" data-cid="658" data-userid="copyeditor 4729" data-username=" (Springer Books)" data-time="1462797367560" title="Deleted by (Springer Books) - 05/9/2016 6:06pm">-</span>times more potent as an inhibitor of GABA-transaminase in vitro than vigabatrin. The additional carbon and fluorine atoms provide enhanced lipophilicity <span class="ins cts-2" data-cid="667" data-userid="copyeditor 4729" data-username=" (Springer Books)" data-time="1462797533931" title="Inserted by (Springer Books) - 05/9/2016 6:08pm">compared with</span><span class="del cts-2" data-cid="666" data-userid="copyeditor 4729" data-username=" (Springer Books)" data-time="1462797531172" title="Deleted by (Springer Books) - 05/9/2016 6:08pm">over that of</span> vigabatrin. After demonstration of substantially reduced retinal toxicity in rodents (<span class="jrnlBibRef" data-type="ruleset" data-citation-string=" R27 ">27</span>) and effectiveness in an animal model of infantile spasms at a much greater potency than vigabatrin (<span class="jrnlBibRef" data-type="ruleset" data-citation-string=" R28 ">28</span>), the compound was licensed to Catalyst Pharmaceuticals which sought and received<span class="ins cts-2" data-cid="740" data-userid="copyeditor 4729" data-username=" (Springer Books)" data-time="1462797698253" title="Inserted by (Springer Books) - 05/9/2016 6:11pm">&nbsp;the</span> orphan drug designation for CPP115 from the <span class="ins cts-2" data-cid="692" data-userid="copyeditor 4729" data-username=" (Springer Books)" data-time="1462797654163" title="Inserted by (Springer Books) - 05/9/2016 6:10pm">U.S. Food and Drug Administration (</span>FDA<span class="ins cts-2" data-cid="731" data-userid="copyeditor 4729" data-username=" (Springer Books)" data-time="1462797672259" title="Inserted by (Springer Books) - 05/9/2016 6:11pm">)</span>. Phase II clinical trials are in progress.</p><p class="jrnlSecPara" align="center" data-xpath="/div[2]/p[10]" uc="true"><img width="480" height="341" id="Picture 14" src="/ecs/article/77142/resources/CH069_F002_BDS.jpg" data-xpath="/div[2]/p[10]/img[1]" data-mce-src="/ecs/article/77142/resources/CH069_F002_BDS.jpg" fontsize="12.0pt" data-primary-extension="eps" data-width="212" data-height="183" data-id="1648032" alt="ecs/article/77142/resources/CH069_F002_BDS.jpg"></p><p class="jrnlFigCaption" data-xpath="/div[2]/p[11]"><b data-xpath="/p[17]/b[1]"><span class="label" data-type="ruleset">Figure <span class="ins cts-1" data-cid="22" data-userid="typesetter 5752" data-username="Bala (Springer Books)" data-time="1462266054278" title="Inserted by Bala (Springer Books) - 05/3/2016 2:30pm">69.</span>2<span class="del cts-1" data-cid="28" data-userid="typesetter 5752" data-username="Bala (Springer Books)" data-time="1462266058306" title="Deleted by Bala (Springer Books) - 05/3/2016 2:30pm">:</span></span></b> The development of brivaracetam leveraged the mechanistic knowledge gained after the release of levetiracetam for clinical use<span class="ins cts-2" data-cid="639" data-userid="copyeditor 4729" data-username=" (Springer Books)" data-time="1462797238299" title="Inserted by (Springer Books) - 05/9/2016 6:03pm">.</span><span class="del cts-2" data-cid="640" data-userid="copyeditor 4729" data-username=" (Springer Books)" data-time="1462797238904" title="Deleted by (Springer Books) - 05/9/2016 6:03pm">;</span> <span class="ins cts-2" data-cid="641" data-userid="copyeditor 4729" data-username=" (Springer Books)" data-time="1462797242869" title="Inserted by (Springer Books) - 05/9/2016 6:04pm">A</span><span class="del cts-2" data-cid="642" data-userid="copyeditor 4729" data-username=" (Springer Books)" data-time="1462797243257" title="Deleted by (Springer Books) - 05/9/2016 6:04pm">a</span> large number of piracetam analogs were synthesized, and the selection process to narrow the candidates for clinical trials employed both in vitro studies and in vivo animal models.</p><p class="jrnlFigCaption" data-xpath="/div[2]/p[12]"><span class="ins cts-2" data-cid="54" data-userid="copyeditor 4729" data-username=" (Springer Books)" data-time="1462878085082" title="Inserted by (Springer Books) - 05/10/2016 4:31pm">MES, <span class="ins cts-1" title="Inserted by (Springer Books) - 05/10/2016 4:31pm" data-cid="NaN" data-userid="4729" data-username=" (Springer Books)" data-time="1462878116089">maximal electroshock seizure.</span></span><br></p><h1 class="jrnlHead1" align="center" data-xpath="/div[2]/h1[2]" bold="true" patternhead="true">THE PRESENT AND THE EMERGING APPROACHES TO NEW AED DEVELOPMENT</h1><p class="jrnlSecPara" data-xpath="/div[2]/p[13]"><span class="jrnlStyledContent" data-background-color="#FFFFFF" style="background-color: #ffffff;" data-mce-style="background-color: #ffffff;">Finally, the emerging approach that is slowly leading us toward<span class="del cts-2" data-cid="10" data-userid="copyeditor 4729" data-username=" (Springer Books)" data-time="1462877156552" title="Deleted by (Springer Books) - 05/10/2016 4:15pm">s</span> what has been called “personalized<span class="del cts-2" data-cid="31" data-userid="copyeditor 4729" data-username=" (Springer Books)" data-time="1462877188709" title="Deleted by (Springer Books) - 05/10/2016 4:16pm">”</span> medicine,<span class="ins cts-4729" title="Inserted by (Springer Books) - 05/10/2016 4:16pm" data-cid="32" data-userid="4729" data-username=" (Springer Books)" data-time="1462877201326">”</span> </span>and recently touted also as “precision medicine,” is a consequence of our increasing prowess in DNA sequencing and bioinformatics. <span class="authorQueryNode Author" id="1462877611122" rid="QRY_1462877611122" data-username=" (Springer Books)" data-time="05/10/2016 4:23pm">The feasibility and economics of this approach </span>to widespread populations is unclear. This approach <span class="del cts-2" data-cid="43" data-userid="copyeditor 4729" data-username=" (Springer Books)" data-time="1462877621022" title="Deleted by (Springer Books) - 05/10/2016 4:23pm">it </span>is a natural consequence of our rapidly increasing knowledge about the genetic basis of some rather difficult to treat seizure disorders that often appear with profound neurodevelopmental disabilities and the hope that early intervention with such targeted therapies may be more successful in controlling the seizures as well as in providing meaningful disease modification. <span class="jrnlTblRef" data-type="ruleset" data-citation-string=" T69. "><span class="authorQueryNode Author" id="1462878780467" rid="QRY_1462878780467" data-username=" (Springer Books)" data-time="05/10/2016 4:43pm">Table </span><span class="ins cts-1" data-cid="30" data-userid="typesetter 5752" data-username="Bala (Springer Books)" data-time="1462266076918" title="Inserted by Bala (Springer Books) - 05/3/2016 2:31pm"><span class="authorQueryNode Author" id="1462878780467" rid="QRY_1462878780467" data-username=" (Springer Books)" data-time="05/10/2016 4:43pm">69.</span></span><span class="authorQueryNode Author" id="1462878780467" rid="QRY_1462878780467" data-username=" (Springer Books)" data-time="05/10/2016 4:43pm">1</span></span><span class="authorQueryNode Author" id="1462878780467" rid="QRY_1462878780467" data-username=" (Springer Books)" data-time="05/10/2016 4:43pm"> </span><span class="del cts-2" data-cid="45" data-userid="copyeditor 4729" data-username=" (Springer Books)" data-time="1462877702052" title="Deleted by (Springer Books) - 05/10/2016 4:25pm"><span class="authorQueryNode Author" id="1462878780467" rid="QRY_1462878780467" data-username=" (Springer Books)" data-time="05/10/2016 4:43pm">b</span><span class="authorQueryNode Author" id="1462878780467" rid="QRY_1462878780467" data-username=" (Springer Books)" data-time="05/10/2016 4:43pm">e</span><span class="authorQueryNode Author" id="1462878780467" rid="QRY_1462878780467" data-username=" (Springer Books)" data-time="05/10/2016 4:43pm">l</span><span class="authorQueryNode Author" id="1462878780467" rid="QRY_1462878780467" data-username=" (Springer Books)" data-time="05/10/2016 4:43pm">o</span><span class="authorQueryNode Author" id="1462878780467" rid="QRY_1462878780467" data-username=" (Springer Books)" data-time="05/10/2016 4:43pm">w</span><span class="authorQueryNode Author" id="1462878780467" rid="QRY_1462878780467" data-username=" (Springer Books)" data-time="05/10/2016 4:43pm"> </span></span><span class="authorQueryNode Author" id="1462878780467" rid="QRY_1462878780467" data-username=" (Springer Books)" data-time="05/10/2016 4:43pm">lists some developments that have not started </span>with classic screens employing the <span class="ins cts-1" title="Inserted by (Springer Books) - 05/10/2016 4:32pm" data-cid="NaN" data-userid="4729" data-username=" (Springer Books)" data-time="1462878141040">maximal electroshock seizure</span><span class="ins cts-2" data-cid="87" data-userid="copyeditor 4729" data-username=" (Springer Books)" data-time="1462878142325" title="Inserted by (Springer Books) - 05/10/2016 4:32pm">&nbsp;(</span>MES<span class="ins cts-2" data-cid="89" data-userid="copyeditor 4729" data-username=" (Springer Books)" data-time="1462878148494" title="Inserted by (Springer Books) - 05/10/2016 4:32pm">)</span>, PTZ, or the 6-Hz models; rather, they have been driven by our evolving knowledge of the molecular basis of normal development (NKCC1/KCC2), discovery of the role of inflammatory signaling in epileptogenesis or serious genetic disorders involving the <span class="ins cts-1" title="Inserted by (Springer Books) - 05/10/2016 4:41pm" data-cid="NaN" data-userid="4729" data-username=" (Springer Books)" data-time="1462878679858">mammalian target of rapamycin<span class="ins cts-2" data-cid="176" data-userid="copyeditor 4729" data-username=" (Springer Books)" data-time="1462878690484" title="Inserted by (Springer Books) - 05/10/2016 4:41pm">&nbsp;(</span></span>mTOR<span class="ins cts-2" data-cid="178" data-userid="copyeditor 4729" data-username=" (Springer Books)" data-time="1462878695764" title="Inserted by (Springer Books) - 05/10/2016 4:41pm">)</span> pathway, genetic basis of severe channelopathies, <span class="ins cts-2" data-cid="208" data-userid="copyeditor 4729" data-username=" (Springer Books)" data-time="1462879030283" title="Inserted by (Springer Books) - 05/10/2016 4:47pm">etc.</span><i fontsize="12.0pt"><span class="del cts-2" data-cid="260" data-userid="copyeditor 4729" data-username=" (Springer Books)" data-time="1462879039541" title="Deleted by (Springer Books) - 05/10/2016 4:47pm">et cetera</span></i><span class="del cts-2" data-cid="269" data-userid="copyeditor 4729" data-username=" (Springer Books)" data-time="1462879042141" title="Deleted by (Springer Books) - 05/10/2016 4:47pm">.</span> Interestingly, some of the compounds of interest represent repurposing of well-known and established medications in use for other purposes such as bumetanide and quinidine. This approach is neither without business risks, nor <span class="ins cts-2" data-cid="271" data-userid="copyeditor 4729" data-username=" (Springer Books)" data-time="1462879114116" title="Inserted by (Springer Books) - 05/10/2016 4:48pm">is it&nbsp;</span>as straight<span class="del cts-2" data-cid="270" data-userid="copyeditor 4729" data-username=" (Springer Books)" data-time="1462879103902" title="Deleted by (Springer Books) - 05/10/2016 4:48pm"> </span>forward in terms of translation, as exemplified by the discouraging results from early clinical trials for VX-765 (<span class="jrnlBibRef" data-type="ruleset" data-citation-string=" R29 ">29</span>) and bumetanide (<span class="jrnlBibRef" data-type="ruleset" data-citation-string=" R30 ">30</span>).</p><p class="jrnlTblCaption" data-xpath="/div[2]/p[14]" id="T1"><b data-xpath="/p[20]/b[1]"><span class="label" data-type="ruleset">Table <span class="ins cts-1" data-cid="33" data-userid="typesetter 5752" data-username="Bala (Springer Books)" data-time="1462266082355" title="Inserted by Bala (Springer Books) - 05/3/2016 2:31pm">69.</span>1<span class="del cts-1" data-cid="36" data-userid="typesetter 5752" data-username="Bala (Springer Books)" data-time="1462266085639" title="Deleted by Bala (Springer Books) - 05/3/2016 2:31pm">.</span></span></b> SELECTED TARGETS OF INTEREST AND POTENTIAL AED<span class="ins cts-2" data-cid="90" data-userid="copyeditor 4729" data-username=" (Springer Books)" data-time="1462878197469" title="Inserted by (Springer Books) - 05/10/2016 4:33pm">s</span><span class="del cts-2" data-cid="91" data-userid="copyeditor 4729" data-username=" (Springer Books)" data-time="1462878199390" title="Deleted by (Springer Books) - 05/10/2016 4:33pm">S</span> THAT <span class="ins cts-2" data-cid="155" data-userid="copyeditor 4729" data-username=" (Springer Books)" data-time="1462878347403" title="Inserted by (Springer Books) - 05/10/2016 4:35pm">THEY&nbsp;</span>INTERACT WITH<span class="del cts-2" data-cid="160" data-userid="copyeditor 4729" data-username=" (Springer Books)" data-time="1462878353165" title="Deleted by (Springer Books) - 05/10/2016 4:35pm"> </span><span class="del cts-2" data-cid="164" data-userid="copyeditor 4729" data-username=" (Springer Books)" data-time="1462878353864" title="Deleted by (Springer Books) - 05/10/2016 4:35pm">THOSE</span></p><div align="center" data-xpath="/div[2]/div[1]"><table class="ecsTable" border="1" cellspacing="0" cellpadding="0" data-xpath="/div[2]/div/table[1]" style="cursor: default;" data-mce-style="cursor: default;"><thead><tr class="headerRow" data-xpath="/div[2]/div/table/thead/tr[1]"><td class="dummyHeader" data-xpath="/div[2]/div/table/thead/tr[1]/td[1]">&nbsp;</td><td class="topHeader" data-col-pos="col-0" data-xpath="/div[2]/div/table/thead/tr[1]/td[2]">A<div class="manualColResizer" data-xpath="/div[2]/div/table/thead/tr[1]/td[2]/div[1]">&nbsp;</div></td><td class="topHeader" data-col-pos="col-1" data-xpath="/div[2]/div/table/thead/tr[1]/td[3]">B<div class="manualColResizer" data-xpath="/div[2]/div/table/thead/tr[1]/td[3]/div[1]">&nbsp;</div></td></tr><tr data-xpath="/div[2]/div/table/thead/tr[2]"><td class="leftHeader" data-xpath="/div[2]/div/table/thead/tr[2]/td[1]"><div class="leftHeaderText" style="margin-top: 25.8889px;" data-xpath="/div[2]/div/table/thead/tr[2]/td[1]/div[1]" data-mce-style="margin-top: 25.8889px;">1</div><div class="manualRowResizer" style="margin-top: 25.8889px;" data-xpath="/div[2]/div/table/thead/tr[2]/td[1]/div[2]" data-mce-style="margin-top: 25.8889px;">&nbsp;</div></td><td width="238" valign="top" data-xpath="/div[2]/div/table/thead/tr[2]/td[2]" data-col-pos="col-0"><p class="jrnlTblBody" data-xpath="/div[2]/div/table/thead/tr[2]/td[2]/p[1]" bold="true"><span class="ins cts-2" data-cid="285" data-userid="copyeditor 4729" data-username=" (Springer Books)" data-time="1462879263455" title="Inserted by (Springer Books) - 05/10/2016 4:51pm">Target</span><br></p></td><td width="182" valign="top" data-xpath="/div[2]/div/table/thead/tr[2]/td[3]" data-col-pos="col-1"><p class="jrnlTblBody" data-xpath="/div[2]/div/table/thead/tr[2]/td[3]/p[1]" bold="true"><span class="ins cts-2" data-cid="292" data-userid="copyeditor 4729" data-username=" (Springer Books)" data-time="1462879268003" title="Inserted by (Springer Books) - 05/10/2016 4:51pm">AED</span><br></p></td></tr><tr data-xpath="/div[2]/div/table/thead/tr[3]"><td class="leftHeader" data-xpath="/div[2]/div/table/thead/tr[3]/td[1]"><div class="leftHeaderText" style="margin-top: 25.8889px;" data-xpath="/div[2]/div/table/thead/tr[3]/td[1]/div[1]" data-mce-style="margin-top: 25.8889px;">2</div><div class="manualRowResizer" style="margin-top: 25.8889px;" data-xpath="/div[2]/div/table/thead/tr[3]/td[1]/div[2]" data-mce-style="margin-top: 25.8889px;">&nbsp;</div></td><td width="238" valign="top" data-xpath="/div[2]/div/table/thead/tr[3]/td[2]" data-col-pos="col-0"><p class="jrnlTblBody" data-xpath="/div[2]/div/table/thead/tr[3]/td[2]/p[1]" bold="true">NKCC1</p></td><td width="182" valign="top" data-xpath="/div[2]/div/table/thead/tr[3]/td[3]" data-col-pos="col-1"><p class="jrnlTblBody" data-xpath="/div[2]/div/table/thead/tr[3]/td[3]/p[1]" bold="true">Bumetanide</p></td></tr></thead><tbody><tr data-xpath="/div[2]/div/table/tbody/tr[1]"><td class="leftHeader" data-xpath="/div[2]/div/table/tbody/tr[1]/td[1]"><div class="leftHeaderText" style="margin-top: 25.8889px;" data-xpath="/div[2]/div/table/tbody/tr[1]/td[1]/div[1]" data-mce-style="margin-top: 25.8889px;">3</div><div class="manualRowResizer" style="margin-top: 25.8889px;" data-xpath="/div[2]/div/table/tbody/tr[1]/td[1]/div[2]" data-mce-style="margin-top: 25.8889px;">&nbsp;</div></td><td width="238" valign="top" data-xpath="/div[2]/div/table/tbody/tr[1]/td[2]" data-col-pos="col-0"><p class="jrnlTblBody" data-xpath="/div[2]/div/table/tbody/tr[1]/td[2]/p[1]" bold="true">ICE/<span class="del cts-2" data-cid="344" data-userid="copyeditor 4729" data-username=" (Springer Books)" data-time="1462881793045" title="Deleted by (Springer Books) - 05/10/2016 5:33pm">C</span><span class="ins cts-2" data-cid="345" data-userid="copyeditor 4729" data-username=" (Springer Books)" data-time="1462881793423" title="Inserted by (Springer Books) - 05/10/2016 5:33pm">c</span>aspase-1</p></td><td width="182" valign="top" data-xpath="/div[2]/div/table/tbody/tr[1]/td[3]" data-col-pos="col-1"><p class="jrnlTblBody" data-xpath="/div[2]/div/table/tbody/tr[1]/td[3]/p[1]" bold="true">VX-765</p></td></tr><tr data-xpath="/div[2]/div/table/tbody/tr[2]"><td class="leftHeader" data-xpath="/div[2]/div/table/tbody/tr[2]/td[1]"><div class="leftHeaderText" style="margin-top: 25.8889px;" data-xpath="/div[2]/div/table/tbody/tr[2]/td[1]/div[1]" data-mce-style="margin-top: 25.8889px;">4</div><div class="manualRowResizer" style="margin-top: 25.8889px;" data-xpath="/div[2]/div/table/tbody/tr[2]/td[1]/div[2]" data-mce-style="margin-top: 25.8889px;">&nbsp;</div></td><td width="238" valign="top" data-xpath="/div[2]/div/table/tbody/tr[2]/td[2]" data-col-pos="col-0"><p class="jrnlTblBody" data-xpath="/div[2]/div/table/tbody/tr[2]/td[2]/p[1]" bold="true">KCNT1 (SLACK)</p></td><td width="182" valign="top" data-xpath="/div[2]/div/table/tbody/tr[2]/td[3]" data-col-pos="col-1"><p class="jrnlTblBody" data-xpath="/div[2]/div/table/tbody/tr[2]/td[3]/p[1]" bold="true">Quinidine</p></td></tr><tr data-xpath="/div[2]/div/table/tbody/tr[3]"><td class="leftHeader" data-xpath="/div[2]/div/table/tbody/tr[3]/td[1]"><div class="leftHeaderText" style="margin-top: 25.8889px;" data-xpath="/div[2]/div/table/tbody/tr[3]/td[1]/div[1]" data-mce-style="margin-top: 25.8889px;">5</div><div class="manualRowResizer" style="margin-top: 25.8889px;" data-xpath="/div[2]/div/table/tbody/tr[3]/td[1]/div[2]" data-mce-style="margin-top: 25.8889px;">&nbsp;</div></td><td width="238" valign="top" data-xpath="/div[2]/div/table/tbody/tr[3]/td[2]" data-col-pos="col-0"><p class="jrnlTblBody" data-xpath="/div[2]/div/table/tbody/tr[3]/td[2]/p[1]" bold="true">mTOR</p></td><td width="182" valign="top" data-xpath="/div[2]/div/table/tbody/tr[3]/td[3]" data-col-pos="col-1"><p class="jrnlTblBody" data-xpath="/div[2]/div/table/tbody/tr[3]/td[3]/p[1]" bold="true">Everolimus, <span class="del cts-2" data-cid="278" data-userid="copyeditor 4729" data-username=" (Springer Books)" data-time="1462879185514" title="Deleted by (Springer Books) - 05/10/2016 4:49pm">S</span><span class="ins cts-2" data-cid="280" data-userid="copyeditor 4729" data-username=" (Springer Books)" data-time="1462879185960" title="Inserted by (Springer Books) - 05/10/2016 4:49pm">s</span>irolimus</p></td></tr><tr data-xpath="/div[2]/div/table/tbody/tr[4]"><td class="leftHeader" data-xpath="/div[2]/div/table/tbody/tr[4]/td[1]"><div class="leftHeaderText" style="margin-top: 25.8889px;" data-xpath="/div[2]/div/table/tbody/tr[4]/td[1]/div[1]" data-mce-style="margin-top: 25.8889px;">6</div><div class="manualRowResizer" style="margin-top: 25.8889px;" data-xpath="/div[2]/div/table/tbody/tr[4]/td[1]/div[2]" data-mce-style="margin-top: 25.8889px;">&nbsp;</div></td><td width="238" valign="top" data-xpath="/div[2]/div/table/tbody/tr[4]/td[2]" data-col-pos="col-0"><p class="jrnlTblBody" data-xpath="/div[2]/div/table/tbody/tr[4]/td[2]/p[1]" bold="true">Glycolysis</p></td><td width="182" valign="top" data-xpath="/div[2]/div/table/tbody/tr[4]/td[3]" data-col-pos="col-1"><p class="jrnlTblBody" data-xpath="/div[2]/div/table/tbody/tr[4]/td[3]/p[1]" bold="true">2-DG</p></td></tr><tr data-xpath="/div[2]/div/table/tbody/tr[5]"><td class="leftHeader" data-xpath="/div[2]/div/table/tbody/tr[5]/td[1]"><div class="leftHeaderText" style="margin-top: 25.8889px;" data-xpath="/div[2]/div/table/tbody/tr[5]/td[1]/div[1]" data-mce-style="margin-top: 25.8889px;">7</div><div class="manualRowResizer" style="margin-top: 25.8889px;" data-xpath="/div[2]/div/table/tbody/tr[5]/td[1]/div[2]" data-mce-style="margin-top: 25.8889px;">&nbsp;</div></td><td width="238" valign="top" data-xpath="/div[2]/div/table/tbody/tr[5]/td[2]" data-col-pos="col-0"><p class="jrnlTblBody" data-xpath="/div[2]/div/table/tbody/tr[5]/td[2]/p[1]" bold="true">PCDH19 mutation</p></td><td width="182" valign="top" data-xpath="/div[2]/div/table/tbody/tr[5]/td[3]" data-col-pos="col-1"><p class="jrnlTblBody" data-xpath="/div[2]/div/table/tbody/tr[5]/td[3]/p[1]" bold="true">Ganoxolone</p></td></tr><tr data-xpath="/div[2]/div/table/tbody/tr[6]"><td class="leftHeader" data-xpath="/div[2]/div/table/tbody/tr[6]/td[1]"><div class="leftHeaderText" style="margin-top: 25.8889px;" data-xpath="/div[2]/div/table/tbody/tr[6]/td[1]/div[1]" data-mce-style="margin-top: 25.8889px;">8</div><div class="manualRowResizer" style="margin-top: 25.8889px;" data-xpath="/div[2]/div/table/tbody/tr[6]/td[1]/div[2]" data-mce-style="margin-top: 25.8889px;">&nbsp;</div></td><td width="238" valign="top" data-xpath="/div[2]/div/table/tbody/tr[6]/td[2]" data-col-pos="col-0"><p class="jrnlTblBody" data-xpath="/div[2]/div/table/tbody/tr[6]/td[2]/p[1]" bold="true">Refractory <span class="del cts-2" data-cid="281" data-userid="copyeditor 4729" data-username=" (Springer Books)" data-time="1462879191705" title="Deleted by (Springer Books) - 05/10/2016 4:49pm">S</span><span class="ins cts-2" data-cid="282" data-userid="copyeditor 4729" data-username=" (Springer Books)" data-time="1462879192163" title="Inserted by (Springer Books) - 05/10/2016 4:49pm">s</span>tatus <span class="del cts-2" data-cid="283" data-userid="copyeditor 4729" data-username=" (Springer Books)" data-time="1462879195376" title="Deleted by (Springer Books) - 05/10/2016 4:49pm">E</span><span class="ins cts-2" data-cid="284" data-userid="copyeditor 4729" data-username=" (Springer Books)" data-time="1462879195847" title="Inserted by (Springer Books) - 05/10/2016 4:49pm">e</span>pilepticus</p></td><td width="182" valign="top" data-xpath="/div[2]/div/table/tbody/tr[6]/td[3]" data-col-pos="col-1"><p class="jrnlTblBody" data-xpath="/div[2]/div/table/tbody/tr[6]/td[3]/p[1]" bold="true">Allopregnanolone</p></td></tr></tbody></table></div><p class="jrnlTblFoot" data-xpath="/div[2]/p[15]"><span class="ins cts-2" data-cid="297" data-userid="copyeditor 4729" data-username=" (Springer Books)" data-time="1462879482345" title="Inserted by (Springer Books) - 05/10/2016 4:54pm">AED, antiepileptic drug; DG, deoxy-<span class="authorQueryNode Typesetter" id="1462959219647" rid="QRY_1462959219647" data-username=" (Springer Books)" data-time="05/11/2016 3:03pm">d</span><span class="authorQueryNode Typesetter" id="1462959219647" rid="QRY_1462959219647" data-username=" (Springer Books)" data-time="05/11/2016 3:03pm">-</span>glucose;&nbsp;ICE, i<span class="ins cts-1" title="Inserted by (Springer Books) - 05/10/2016 4:54pm" data-cid="NaN" data-userid="4729" data-username=" (Springer Books)" data-time="1462879487123">nterleukin converting enzyme;<span class="ins cts-2" data-cid="305" data-userid="copyeditor 4729" data-username=" (Springer Books)" data-time="1462879489587" title="Inserted by (Springer Books) - 05/10/2016 4:54pm">&nbsp;mTOR,&nbsp;<span class="ins cts-1" title="Inserted by (Springer Books) - 05/10/2016 4:55pm" data-cid="NaN" data-userid="4729" data-username=" (Springer Books)" data-time="1462879522465">mammalian target of <span class="authorQueryNode Author" id="1462881745485" rid="QRY_1462881745485" data-username=" (Springer Books)" data-time="05/10/2016 5:32pm">rapamycin<span class="ins cts-2" data-cid="498" data-userid="copyeditor 4729" data-username=" (Springer Books)" data-time="1462960041803" title="Inserted by (Springer Books) - 05/11/2016 3:17pm">; PCDH, &nbsp;protocadherin</span>.</span></span></span></span></span><br></p><p class="jrnlSecPara" data-xpath="/div[2]/p[16]">The rationale for the development of VX-765 was based on the increasing awareness of the role of inflammatory signaling in a variety of neurological disorders and the finding that inhibition of interleukin converting enzyme (ICE), also known as caspase-1, by VX-765 was beneficial in several mouse models of epilepsy, including mice that displayed drug-resistant chronic epileptic activity (<span class="jrnlBibRef" data-type="ruleset" data-citation-string=" R31 R32 ">31,32</span>). However, the Phase II trial of VX-765 showed <span class="ins cts-2" data-cid="346" data-userid="copyeditor 4729" data-username=" (Springer Books)" data-time="1462882015825" title="Inserted by (Springer Books) - 05/10/2016 5:36pm">a&nbsp;</span>very <span class="ins cts-2" data-cid="349" data-userid="copyeditor 4729" data-username=" (Springer Books)" data-time="1462882025584" title="Inserted by (Springer Books) - 05/10/2016 5:37pm">mediocre</span><span class="del cts-2" data-cid="348" data-userid="copyeditor 4729" data-username=" (Springer Books)" data-time="1462882022352" title="Deleted by (Springer Books) - 05/10/2016 5:37pm">lackluster</span> effect in humans (<span class="jrnlBibRef" data-type="ruleset" data-citation-string=" R29 ">29</span>), <span class="ins cts-2" data-cid="379" data-userid="copyeditor 4729" data-username=" (Springer Books)" data-time="1462882090202" title="Inserted by (Springer Books) - 05/10/2016 5:38pm">based on which</span><span class="del cts-2" data-cid="375" data-userid="copyeditor 4729" data-username=" (Springer Books)" data-time="1462882083615" title="Deleted by (Springer Books) - 05/10/2016 5:38pm">and</span> the company, Vertex Pharmaceuticals, <span class="del cts-2" data-cid="398" data-userid="copyeditor 4729" data-username=" (Springer Books)" data-time="1462882098698" title="Deleted by (Springer Books) - 05/10/2016 5:38pm">has </span>stopped further testing<span class="del cts-2" data-cid="403" data-userid="copyeditor 4729" data-username=" (Springer Books)" data-time="1462882330888" title="Deleted by (Springer Books) - 05/10/2016 5:42pm">;</span> and the compound is no longer covered in the most recent Eilat conference on AEDs under development (<span class="jrnlBibRef" data-type="ruleset" data-citation-string=" R1 ">1</span>). Likewise, the rationale for a human trial for bumetanide was the knowledge of the developmental switch in Cl<sup><span class="ins cts-1" title="Inserted by (Springer Books) - 05/10/2016 5:54pm" data-cid="NaN" data-userid="4729" data-username=" (Springer Books)" data-time="1462883074145">-</span></sup><sup fontsize="12.0pt"><span class="del cts-2" data-cid="406" data-userid="copyeditor 4729" data-username=" (Springer Books)" data-time="1462883085679" title="Deleted by (Springer Books) - 05/10/2016 5:54pm">-</span></sup> transporters and the likelihood that in the immature brain blockade of the neonatal <span class="jrnlStyledContent" data-background-color="#FFFFFF" style="background-color: #ffffff;" data-mce-style="background-color: #ffffff;">transporter NKCC1 might improve responsiveness to phenobarbital, <span class="ins cts-2" data-cid="12" data-userid="copyeditor 4729" data-username=" (Springer Books)" data-time="1462944014524" title="Inserted by (Springer Books) - 05/11/2016 10:50am">as&nbsp;</span>supported by experiments on hippocampal </span>slices (<span class="jrnlBibRef" data-type="ruleset" data-citation-string=" R33 ">33</span>). One successful result in a case report (<span class="jrnlBibRef" data-type="ruleset" data-citation-string=" R34 ">34</span>) <span class="ins cts-2" data-cid="415" data-userid="copyeditor 4729" data-username=" (Springer Books)" data-time="1462883712802" title="Inserted by (Springer Books) - 05/10/2016 6:05pm">is</span><span class="del cts-2" data-cid="412" data-userid="copyeditor 4729" data-username=" (Springer Books)" data-time="1462883708054" title="Deleted by (Springer Books) - 05/10/2016 6:05pm">was</span> clearly insufficient to prognosticate success in a larger clinical trial. T<span class="ins cts-2" data-cid="154" data-userid="copyeditor 4729" data-username=" (Springer Books)" data-time="1462944304143" title="Inserted by (Springer Books) - 05/11/2016 10:55am">he authors suggest&nbsp;</span><span class="ins cts-2" data-cid="68" data-userid="copyeditor 4729" data-username=" (Springer Books)" data-time="1462944061833" title="Inserted by (Springer Books) - 05/11/2016 10:51am">that</span><span class="del cts-2" data-cid="24" data-userid="copyeditor 4729" data-username=" (Springer Books)" data-time="1462944051037" title="Deleted by (Springer Books) - 05/11/2016 10:50am">One wonders if</span> more studies in live animal seizure models (in vivo) employing different species and seizure models <span class="ins cts-2" data-cid="96" data-userid="copyeditor 4729" data-username=" (Springer Books)" data-time="1462944079996" title="Inserted by (Springer Books) - 05/11/2016 10:51am">may</span><span class="del cts-2" data-cid="102" data-userid="copyeditor 4729" data-username=" (Springer Books)" data-time="1462944081180" title="Deleted by (Springer Books) - 05/11/2016 10:51am">might have</span> improve<span class="del cts-2" data-cid="118" data-userid="copyeditor 4729" data-username=" (Springer Books)" data-time="1462944086079" title="Deleted by (Springer Books) - 05/11/2016 10:51am">d</span> the predictive ability for a successful translation. Just as likely is the possibility that NKCC1 is a relevant target, but that bumetanide may not be the best agent to leverage <span class="ins cts-2" data-cid="185" data-userid="copyeditor 4729" data-username=" (Springer Books)" data-time="1462944337541" title="Inserted by (Springer Books) - 05/11/2016 10:55am">the</span><span class="del cts-2" data-cid="190" data-userid="copyeditor 4729" data-username=" (Springer Books)" data-time="1462944340275" title="Deleted by (Springer Books) - 05/11/2016 10:55am">that</span> mechanism given its poor <span class="ins cts-2" data-cid="13" data-userid="copyeditor 4729" data-username=" (Springer Books)" data-time="1462946544273" title="Inserted by (Springer Books) - 05/11/2016 11:32am">central nervous system (</span>CNS<span class="ins cts-2" data-cid="82" data-userid="copyeditor 4729" data-username=" (Springer Books)" data-time="1462946554558" title="Inserted by (Springer Books) - 05/11/2016 11:32am">)</span> penetration and its other liabilities for toxicity.</p><p class="jrnlSecPara" data-xpath="/div[2]/p[17]">The role played by gain-of-function mutations in the gene coding for KCNT1 (<span class="authorQueryNode Author" id="1462948009497" rid="QRY_1462948009497" data-username=" (Springer Books)" data-time="05/11/2016 11:56am">Slack)</span> channels in highly refractory forms of seizures such as malignant migrating partial seizures of infancy (MMPSI) and some forms of autosomal dominant nocturnal frontal lobe epilepsy (ADNF<span class="ins cts-2" data-cid="83" data-userid="copyeditor 4729" data-username=" (Springer Books)" data-time="1462950932838" title="Inserted by (Springer Books) - 05/11/2016 12:45pm">L</span>E) <span class="ins cts-2" data-cid="86" data-userid="copyeditor 4729" data-username=" (Springer Books)" data-time="1462951011833" title="Inserted by (Springer Books) - 05/11/2016 12:46pm">is</span><span class="del cts-2" data-cid="92" data-userid="copyeditor 4729" data-username=" (Springer Books)" data-time="1462951013831" title="Deleted by (Springer Books) - 05/11/2016 12:46pm">are</span> described in some detail in <span class="del cts-2" data-cid="95" data-userid="copyeditor 4729" data-username=" (Springer Books)" data-time="1462951022490" title="Deleted by (Springer Books) - 05/11/2016 12:47pm">the first section of this book in </span>Chapter 3. Much excitement was generated by the observation from <span class="jrnlStyledContent" data-background-color="#FFFFFF" style="background-color: #ffffff;" data-mce-style="background-color: #ffffff;">Steven Petrou’s group that the gain<span class="ins cts-2" data-cid="17" data-userid="copyeditor 4729" data-username=" (Springer Books)" data-time="1462954235411" title="Inserted by (Springer Books) - 05/11/2016 1:40pm">&nbsp;</span><span class="del cts-2" data-cid="26" data-userid="copyeditor 4729" data-username=" (Springer Books)" data-time="1462954236004" title="Deleted by (Springer Books) - 05/11/2016 1:40pm">-</span>of<span class="ins cts-2" data-cid="46" data-userid="copyeditor 4729" data-username=" (Springer Books)" data-time="1462954238580" title="Inserted by (Springer Books) - 05/11/2016 1:40pm">&nbsp;</span><span class="del cts-2" data-cid="47" data-userid="copyeditor 4729" data-username=" (Springer Books)" data-time="1462954239712" title="Deleted by (Springer Books) - 05/11/2016 1:40pm">-</span>function could be blocked by quinidine when </span>studied in the in vitro expression system employing <i fontsize="12.0pt">Xenopus</i> oocytes (<span class="jrnlBibRef" data-type="ruleset" data-citation-string=" R35 ">35</span>). Because quinidine is an already available drug, trials with individual cases was not difficult. However, differing results have been reported by two groups of investigators in different patients possessing the same heterozygous R428Q gain-of-function mutation presenting with MMPSI (<span class="jrnlBibRef" data-type="ruleset" data-citation-string=" R36 R37 ">36,<span class="del cts-2" data-cid="48" data-userid="copyeditor 4729" data-username=" (Springer Books)" data-time="1462954305497" title="Deleted by (Springer Books) - 05/11/2016 1:41pm"> </span>37</span>). The successful case may have benefited from earlier institution of therapy at 3 years (<span class="jrnlBibRef" data-type="ruleset" data-citation-string=" R36 ">36</span>) compared <span class="ins cts-2" data-cid="49" data-userid="copyeditor 4729" data-username=" (Springer Books)" data-time="1462954352792" title="Inserted by (Springer Books) - 05/11/2016 1:42pm">with</span><span class="del cts-2" data-cid="57" data-userid="copyeditor 4729" data-username=" (Springer Books)" data-time="1462954354092" title="Deleted by (Springer Books) - 05/11/2016 1:42pm">to</span> the patient who received treatment with quinidine at 5 years of age (<span class="jrnlBibRef" data-type="ruleset" data-citation-string=" R37 ">37</span>). However, <span class="ins cts-2" data-cid="64" data-userid="copyeditor 4729" data-username=" (Springer Books)" data-time="1462954367376" title="Inserted by (Springer Books) - 05/11/2016 1:42pm">as</span><span class="del cts-2" data-cid="66" data-userid="copyeditor 4729" data-username=" (Springer Books)" data-time="1462954368840" title="Deleted by (Springer Books) - 05/11/2016 1:42pm">since</span> both patients began exhibiting severe seizures in the first few weeks of life, it is more likely that differences in genetic background played a greater role. Mikati <span class="ins cts-2" data-cid="74" data-userid="copyeditor 4729" data-username=" (Springer Books)" data-time="1462954420344" title="Inserted by (Springer Books) - 05/11/2016 1:43pm">et al</span><span class="del cts-2" data-cid="88" data-userid="copyeditor 4729" data-username=" (Springer Books)" data-time="1462954422426" title="Deleted by (Springer Books) - 05/11/2016 1:43pm">and colleagues</span> reported successful treatment of a case of KCNT1 encephalopathy presenting as MMPSI, but not the other <span class="ins cts-2" data-cid="119" data-userid="copyeditor 4729" data-username=" (Springer Books)" data-time="1462954516476" title="Inserted by (Springer Books) - 05/11/2016 1:45pm">case&nbsp;</span>presenting with ADNF<span class="ins cts-2" data-cid="85" data-userid="copyeditor 4729" data-username=" (Springer Books)" data-time="1462950960241" title="Inserted by (Springer Books) - 05/11/2016 12:46pm">L</span>E (<span class="jrnlBibRef" data-type="ruleset" data-citation-string=" R38 ">38</span>). <span class="ins cts-2" data-cid="124" data-userid="copyeditor 4729" data-username=" (Springer Books)" data-time="1462954693783" title="Inserted by (Springer Books) - 05/11/2016 1:48pm">Although&nbsp;</span><span class="del cts-2" data-cid="133" data-userid="copyeditor 4729" data-username=" (Springer Books)" data-time="1462954696848" title="Deleted by (Springer Books) - 05/11/2016 1:48pm">T</span><span class="ins cts-2" data-cid="134" data-userid="copyeditor 4729" data-username=" (Springer Books)" data-time="1462954696999" title="Inserted by (Springer Books) - 05/11/2016 1:48pm">t</span>hese results<span class="del cts-2" data-cid="135" data-userid="copyeditor 4729" data-username=" (Springer Books)" data-time="1462954701910" title="Deleted by (Springer Books) - 05/11/2016 1:48pm">, while</span> support<span class="del cts-2" data-cid="142" data-userid="copyeditor 4729" data-username=" (Springer Books)" data-time="1462954706140" title="Deleted by (Springer Books) - 05/11/2016 1:48pm">ive of</span> the concept of “precision medicine,” <span class="ins cts-2" data-cid="148" data-userid="copyeditor 4729" data-username=" (Springer Books)" data-time="1462954730166" title="Inserted by (Springer Books) - 05/11/2016 1:48pm">they&nbsp;</span>also <span class="ins cts-2" data-cid="153" data-userid="copyeditor 4729" data-username=" (Springer Books)" data-time="1462954734848" title="Inserted by (Springer Books) - 05/11/2016 1:48pm">indicate</span><span class="del cts-2" data-cid="166" data-userid="copyeditor 4729" data-username=" (Springer Books)" data-time="1462954737487" title="Deleted by (Springer Books) - 05/11/2016 1:48pm">caution</span> that translation is quite complicated.</p><p class="jrnlSecPara" data-xpath="/div[2]/p[18]">The <span class="del cts-2" data-cid="173" data-userid="copyeditor 4729" data-username=" (Springer Books)" data-time="1462954770425" title="Deleted by (Springer Books) - 05/11/2016 1:49pm">mammalian target of rapamycin (</span>mTOR<span class="del cts-2" data-cid="174" data-userid="copyeditor 4729" data-username=" (Springer Books)" data-time="1462954772490" title="Deleted by (Springer Books) - 05/11/2016 1:49pm">)</span> pathway emerged initially <span class="ins cts-2" data-cid="179" data-userid="copyeditor 4729" data-username=" (Springer Books)" data-time="1462957560144" title="Inserted by (Springer Books) - 05/11/2016 2:36pm">as a potential method&nbsp;</span>for the treatment of subependymal giant-cell astrocytomas (SEGA<span class="ins cts-2" data-cid="175" data-userid="copyeditor 4729" data-username=" (Springer Books)" data-time="1462954800937" title="Inserted by (Springer Books) - 05/11/2016 1:50pm">s</span>) in patients with tuberous sclerosis, a disease attributed to mutations in <span class="ins cts-1" title="Inserted by (Springer Books) - 05/11/2016 2:42pm" data-cid="NaN" data-userid="4729" data-username=" (Springer Books)" data-time="1462957921440">tuberous sclerosis</span><span class="ins cts-2" data-cid="252" data-userid="copyeditor 4729" data-username=" (Springer Books)" data-time="1462957923324" title="Inserted by (Springer Books) - 05/11/2016 2:42pm">&nbsp;complex 1 or 2 (</span>TSC1 or TSC2<span class="ins cts-2" data-cid="275" data-userid="copyeditor 4729" data-username=" (Springer Books)" data-time="1462957943061" title="Inserted by (Springer Books) - 05/11/2016 2:42pm">)</span>. It came to be recognized that the <span class="del cts-2" data-cid="720" data-userid="copyeditor 4729" data-username=" (Springer Books)" data-time="1462962614043" title="Deleted by (Springer Books) - 05/11/2016 4:00pm">the </span>role played by this signaling pathway (that also involves PTEN, DEPDC5, and a host of other players) is not only in growth and proliferation, but also in neural plasticity involving regulation of ion channel expression, neurotransmitter receptor expression, neurite outgrowth<span class="ins cts-2" data-cid="177" data-userid="copyeditor 4729" data-username=" (Springer Books)" data-time="1462955886496" title="Inserted by (Springer Books) - 05/11/2016 2:08pm">,</span> and overall synaptic plasticity. These considerations led investigat<span class="ins cts-2" data-cid="207" data-userid="copyeditor 4729" data-username=" (Springer Books)" data-time="1462957739536" title="Inserted by (Springer Books) - 05/11/2016 2:38pm">ors</span><span class="del cts-2" data-cid="213" data-userid="copyeditor 4729" data-username=" (Springer Books)" data-time="1462957741705" title="Deleted by (Springer Books) - 05/11/2016 2:39pm">ions</span> to examine the role of this pathway in epilepsy and the potential for its pharmacologic modulation in modifying epileptogenesis as well as seizures. Investigations <span class="ins cts-2" data-cid="222" data-userid="copyeditor 4729" data-username=" (Springer Books)" data-time="1462957778301" title="Inserted by (Springer Books) - 05/11/2016 2:39pm">by</span><span class="del cts-2" data-cid="220" data-userid="copyeditor 4729" data-username=" (Springer Books)" data-time="1462957774693" title="Deleted by (Springer Books) - 05/11/2016 2:39pm">in the laboratory of</span> Michael Wong<span class="ins cts-2" data-cid="244" data-userid="copyeditor 4729" data-username=" (Springer Books)" data-time="1462957790528" title="Inserted by (Springer Books) - 05/11/2016 2:39pm">'s group</span> demonstrated that early treatment with rapamycin prevented the development of epilepsy and premature death observed in a mouse model of TSC generated by a conditional knock<span class="del cts-2" data-cid="277" data-userid="copyeditor 4729" data-username=" (Springer Books)" data-time="1462958023653" title="Deleted by (Springer Books) - 05/11/2016 2:43pm">-</span>out of the TSC1 gene in glial fibrillary acidic protein (GFAP) expressing cells (<span class="jrnlBibRef" data-type="ruleset" data-citation-string=" R39 ">39</span>). When rapamycin treatment was applied to mice that had already developed epilepsy, the treatment still suppressed seizures and prolonged survival of those mice. The same <span class="ins cts-2" data-cid="286" data-userid="copyeditor 4729" data-username=" (Springer Books)" data-time="1462958055348" title="Inserted by (Springer Books) - 05/11/2016 2:44pm">investigators</span><span class="del cts-2" data-cid="303" data-userid="copyeditor 4729" data-username=" (Springer Books)" data-time="1462958060484" title="Deleted by (Springer Books) - 05/11/2016 2:44pm">laboratory</span> showed that rapamycin treatment also interfered with the development of limbic epilepsy after kainic acid-induced status epilepticus in Sprague Dawley rats (<span class="jrnlBibRef" data-type="ruleset" data-citation-string=" R40 ">40</span>). However, in the pilocarpine-induced status epilepticus model of temporal lobe epilepsy (TLE), treatment with high<span class="ins cts-2" data-cid="314" data-userid="copyeditor 4729" data-username=" (Springer Books)" data-time="1462958177007" title="Inserted by (Springer Books) - 05/11/2016 2:46pm">-</span><span class="del cts-2" data-cid="315" data-userid="copyeditor 4729" data-username=" (Springer Books)" data-time="1462958177651" title="Deleted by (Springer Books) - 05/11/2016 2:46pm"> </span>dose rapamycin abolished mossy fiber sprouting (a feature seen in both human and rodent models of TLE), but did not protect the animals from developing recurrent spontaneous seizures (<span class="jrnlBibRef" data-type="ruleset" data-citation-string=" R41 ">41</span>). Nevertheless, when the rapamycin analog, everolimus, was used to treat SEGAs in children, the results showed that many children enjoyed a reduction in seizure frequency in addition to a reduction in the volume of tumors (<span class="jrnlBibRef" data-type="ruleset" data-citation-string=" R42 ">42</span>). These results encouraged Krueger <span class="ins cts-2" data-cid="316" data-userid="copyeditor 4729" data-username=" (Springer Books)" data-time="1462958248009" title="Inserted by (Springer Books) - 05/11/2016 2:47pm">et al</span><span class="del cts-2" data-cid="322" data-userid="copyeditor 4729" data-username=" (Springer Books)" data-time="1462958251555" title="Deleted by (Springer Books) - 05/11/2016 2:47pm">and colleagues</span> to undertake a prospective trial of everolimus specifically for the evaluation of seizure reduction (<span class="jrnlBibRef" data-type="ruleset" data-citation-string=" R43 ">43</span>). They enrolled 20 patients who were treated with everolimus. <span class="del cts-2" data-cid="338" data-userid="copyeditor 4729" data-username=" (Springer Books)" data-time="1462958279433" title="Deleted by (Springer Books) - 05/11/2016 2:47pm">12 o</span><span class="ins cts-2" data-cid="342" data-userid="copyeditor 4729" data-username=" (Springer Books)" data-time="1462958283337" title="Inserted by (Springer Books) - 05/11/2016 2:48pm">O</span>f <span class="ins cts-2" data-cid="343" data-userid="copyeditor 4729" data-username=" (Springer Books)" data-time="1462958286120" title="Inserted by (Springer Books) - 05/11/2016 2:48pm">the&nbsp;</span>20 subjects<span class="ins cts-2" data-cid="352" data-userid="copyeditor 4729" data-username=" (Springer Books)" data-time="1462958291101" title="Inserted by (Springer Books) - 05/11/2016 2:48pm">, 12</span> attained a reduction in seizure frequency by =50%. Overall, seizures were reduced in 17 of the 20 <span class="ins cts-2" data-cid="361" data-userid="copyeditor 4729" data-username=" (Springer Books)" data-time="1462958462595" title="Inserted by (Springer Books) - 05/11/2016 2:51pm">patients&nbsp;</span>by a median reduction of 73% (<em><span class="ins cts-2" data-cid="357" data-userid="copyeditor 4729" data-username=" (Springer Books)" data-time="1462958413414" title="Inserted by (Springer Books) - 05/11/2016 2:50pm">P</span></em><span class="del cts-2" data-cid="358" data-userid="copyeditor 4729" data-username=" (Springer Books)" data-time="1462958416846" title="Deleted by (Springer Books) - 05/11/2016 2:50pm">p</span><span class="ins cts-2" data-cid="360" data-userid="copyeditor 4729" data-username=" (Springer Books)" data-time="1462958432529" title="Inserted by (Springer Books) - 05/11/2016 2:50pm">&nbsp;</span>&lt;<span class="ins cts-2" data-cid="359" data-userid="copyeditor 4729" data-username=" (Springer Books)" data-time="1462958430124" title="Inserted by (Springer Books) - 05/11/2016 2:50pm">&nbsp;</span>0.001) and families reported an improvement in behavior and quality of life (<span class="jrnlBibRef" data-type="ruleset" data-citation-string=" R43 ">43</span>). Similar encouraging results have been reported by Cardamone et al based on treatment with either rapamycin (sirolimus) or everolimus (<span class="jrnlBibRef" data-type="ruleset" data-citation-string=" R44 ">44</span>). Much research remains to be done to see if such treatment<span class="ins cts-2" data-cid="380" data-userid="copyeditor 4729" data-username=" (Springer Books)" data-time="1462958615109" title="Inserted by (Springer Books) - 05/11/2016 2:53pm">s</span> can be applied safely to very young infants diagnosed with TSC, even before they develop infantile spasms<span class="del cts-2" data-cid="382" data-userid="copyeditor 4729" data-username=" (Springer Books)" data-time="1462958627673" title="Deleted by (Springer Books) - 05/11/2016 2:53pm">,</span> or begin to exhibit traits of autism. The emerging applications of mTOR inhibitors <span class="ins cts-2" data-cid="387" data-userid="copyeditor 4729" data-username=" (Springer Books)" data-time="1462958952285" title="Inserted by (Springer Books) - 05/11/2016 2:59pm">indicate that they&nbsp;</span>appear to be enjoying a higher level of translational success. Trials are under way now for the treatment of children with Sturge<span class="ins cts-4729" title="Inserted by (Springer Books) - 05/11/2016 2:58pm" data-cid="385" data-userid="4729" data-username=" (Springer Books)" data-time="1462958921617">–</span><span class="del cts-2" data-cid="386" data-userid="copyeditor 4729" data-username=" (Springer Books)" data-time="1462958925513" title="Deleted by (Springer Books) - 05/11/2016 2:58pm">-</span>Weber syndrome (<span class="jrnlBibRef" data-type="ruleset" data-citation-string=" R45 ">45</span>). The business risk of investments in everolimus for epilepsy-related disorders is mitigated by the promise for that drug in a very wide-range of tumors.</p><p class="jrnlSecPara" data-xpath="/div[2]/p[19]">The development of 2-deoxy-<span class="ins cts-2" data-cid="448" data-userid="copyeditor 4729" data-username=" (Springer Books)" data-time="1462959235750" title="Inserted by (Springer Books) - 05/11/2016 3:03pm"><span class="authorQueryNode Typesetter" id="1462959263508" rid="QRY_1462959263508" data-username=" (Springer Books)" data-time="05/11/2016 3:04pm">d</span></span><span class="del cts-2" data-cid="449" data-userid="copyeditor 4729" data-username=" (Springer Books)" data-time="1462959235981" title="Deleted by (Springer Books) - 05/11/2016 3:03pm"><span class="authorQueryNode Typesetter" id="1462959263508" rid="QRY_1462959263508" data-username=" (Springer Books)" data-time="05/11/2016 3:04pm">D</span></span>-glucose (2-DG) as a novel anticonvulsant is an interesting example of <span class="ins cts-2" data-cid="452" data-userid="copyeditor 4729" data-username=" (Springer Books)" data-time="1462959422660" title="Inserted by (Springer Books) - 05/11/2016 3:07pm">the&nbsp;</span>bedside<span class="ins cts-1" title="Inserted by (Springer Books) - 05/11/2016 3:04pm" data-cid="NaN" data-userid="4729" data-username=" (Springer Books)" data-time="1462959297033">–</span><span class="del cts-2" data-cid="450" data-userid="copyeditor 4729" data-username=" (Springer Books)" data-time="1462959299120" title="Deleted by (Springer Books) - 05/11/2016 3:04pm">-</span>bench<span class="ins cts-1" title="Inserted by (Springer Books) - 05/11/2016 3:05pm" data-cid="NaN" data-userid="4729" data-username=" (Springer Books)" data-time="1462959303068">–</span><span class="del cts-2" data-cid="451" data-userid="copyeditor 4729" data-username=" (Springer Books)" data-time="1462959304906" title="Deleted by (Springer Books) - 05/11/2016 3:05pm">-</span>bedside cycle. The ketogenic diet has been used in the treatment of epilepsy for a long time, and many mechanisms are likely to contribute to its effectiveness (<span class="jrnlBibRef" data-type="ruleset" data-citation-string=" R46 R47 R48 ">46<span class="del cts-5752" title="Inserted by Bala (Springer Books) - 05/03/2016 2:47pm" data-cid="41" data-userid="5752" data-username="Bala (Springer Books)" data-time="1462267045623">-</span><span class="ins cts-5752" title="Inserted by Bala (Springer Books) - 05/03/2016 2:47pm" data-cid="42" data-userid="5752" data-username="Bala (Springer Books)" data-time="1462267045629">–</span>48</span>). In 2005, Pfeifer and Thiele reported that a less stringent variation of the ketogenic diet designed to reduce glycolytic flux, but short of producing robust ketosis, was also effective in controlling seizures in children (<span class="jrnlBibRef" data-type="ruleset" data-citation-string=" R49 ">49</span>). A scientific basis for this was proposed by Ma et al, who suggested that reduced glycolytic ATP synthesis (rather than mitochondrial ATP synthesis) resulting in low ATP levels near the plasma membrane (ATP<sub fontsize="12.0pt">pm</sub>) can disinhibit K<sub fontsize="12.0pt">ATP</sub> channels and reduce electrical activity (<span class="jrnlBibRef" data-type="ruleset" data-citation-string=" R50 ">50</span>). Experiments supporting <span class="ins cts-2" data-cid="456" data-userid="copyeditor 4729" data-username=" (Springer Books)" data-time="1462959539576" title="Inserted by (Springer Books) - 05/11/2016 3:08pm">this</span><span class="del cts-2" data-cid="460" data-userid="copyeditor 4729" data-username=" (Springer Books)" data-time="1462959541072" title="Deleted by (Springer Books) - 05/11/2016 3:09pm">that</span> concept furthered the findings of Garriga-Canut et al (<span class="jrnlBibRef" data-type="ruleset" data-citation-string=" R51 ">51</span>) who had shown that the administration of 2-DG to rats retarded kindling acquisition, and that this effect was mediated through transcription factor NRSF-mediated downregulation of brain derived neurotropic factor (BDNF) and its TrkB receptor expression. These findings collectively provided the impetus for preparing 2-DG for an investigational new drug application (INDA) and clinical trials. However, chronic administration of 2-DG to two different species of rats produced cardiac myocyte toxicity with increasing vacuolization and hastened mortality as a result of heart failure as well as increased incidence of pheochromocytoma in the adrenal medulla (<span class="jrnlBibRef" data-type="ruleset" data-citation-string=" R52 ">52</span>). A Phase I/II dose-escalation human study for prostate cancer revealed dose-limiting grade 3 asymptomatic QTc prolongation (<span class="jrnlBibRef" data-type="ruleset" data-citation-string=" R53 ">53</span>). The recent description of potential biomarkers for 2-DG-associated cardiotoxicity (<span class="jrnlBibRef" data-type="ruleset" data-citation-string=" R54 ">54</span>) will have to be validated in humans, as development of this product moves forward. The progression from human experience with the low-glycemic index diet through animal epilepsy models and in vitro mechanistic demonstrations of the use of 2-DG as “metabolism-based” epilepsy therapy<span class="del cts-2" data-cid="467" data-userid="copyeditor 4729" data-username=" (Springer Books)" data-time="1462959797594" title="Deleted by (Springer Books) - 05/11/2016 3:13pm">,</span> to clinical trials in humans with 2-DG represent<span class="ins cts-2" data-cid="468" data-userid="copyeditor 4729" data-username=" (Springer Books)" data-time="1462959821612" title="Inserted by (Springer Books) - 05/11/2016 3:13pm">s</span> a very interesting cycle. But the “hiccups” caused by the discoveries of unexpected toxicity highlights the delays and costs associated with the AED development process.</p><p class="jrnlSecPara" data-xpath="/div[2]/p[20]">Yet another example of a translational approach that began at first with findings in patients<span class="del cts-2" data-cid="476" data-userid="copyeditor 4729" data-username=" (Springer Books)" data-time="1462959896071" title="Deleted by (Springer Books) - 05/11/2016 3:14pm">,</span> but culminated in the initiation of trials after laboratory science <span class="ins cts-2" data-cid="477" data-userid="copyeditor 4729" data-username=" (Springer Books)" data-time="1462959927698" title="Inserted by (Springer Books) - 05/11/2016 3:15pm">is</span><span class="del cts-2" data-cid="479" data-userid="copyeditor 4729" data-username=" (Springer Books)" data-time="1462959928349" title="Deleted by (Springer Books) - 05/11/2016 3:15pm">involves</span> the story of the discovery of the role of neurosteroids in <span class="del cts-2" data-cid="528" data-userid="copyeditor 4729" data-username=" (Springer Books)" data-time="1462960156413" title="Deleted by (Springer Books) - 05/11/2016 3:19pm">P</span><span class="ins cts-2" data-cid="529" data-userid="copyeditor 4729" data-username=" (Springer Books)" data-time="1462960156781" title="Inserted by (Springer Books) - 05/11/2016 3:19pm">p</span>rotocadherin 19 female limited epilepsy (PCDH19-FE) (<span class="jrnlBibRef" data-type="ruleset" data-citation-string=" R55 ">55</span>). This is an interesting X-linked disorder, with clinical expression in females, while male carriers are typically symptomatic. Tan et al undertook a study of genes with gender-biased expression in a population of patients with this <span class="ins cts-2" data-cid="530" data-userid="copyeditor 4729" data-username=" (Springer Books)" data-time="1462960245388" title="Inserted by (Springer Books) - 05/11/2016 3:20pm">dis</span>order, female controls, as well as male carriers and male controls (<span class="jrnlBibRef" data-type="ruleset" data-citation-string=" R56 ">56</span>). They narrowed their findings to the aldo-keto reductase gene AKR1C3 involved in steroid metabolism. They identified reduced mRNA and protein levels of AKR1C3 and coincident reductions in the blood levels of allopregnanolone (<span class="jrnlBibRef" data-type="ruleset" data-citation-string=" R56 ">56</span>). Allopregnanolone can enhance GABA-mediated Cl<sup><span class="ins cts-4729" title="Inserted by (Springer Books) - 05/11/2016 3:22pm" data-cid="533" data-userid="4729" data-username=" (Springer Books)" data-time="1462960346932">-</span></sup><sup fontsize="12.0pt"><span class="del cts-2" data-cid="534" data-userid="copyeditor 4729" data-username=" (Springer Books)" data-time="1462960359599" title="Deleted by (Springer Books) - 05/11/2016 3:22pm">-</span></sup> currents at <span class="ins cts-2" data-cid="536" data-userid="copyeditor 4729" data-username=" (Springer Books)" data-time="1462960364097" title="Inserted by (Springer Books) - 05/11/2016 3:22pm">gamma</span><span class="del cts-2" data-cid="541" data-userid="copyeditor 4729" data-username=" (Springer Books)" data-time="1462960366527" title="Deleted by (Springer Books) - 05/11/2016 3:22pm">?</span>-subunit containing synaptic GABA receptors that mediate phasic inhibition as well as <span class="ins cts-2" data-cid="542" data-userid="copyeditor 4729" data-username=" (Springer Books)" data-time="1462960435031" title="Inserted by (Springer Books) - 05/11/2016 3:23pm">delta</span><span class="del cts-2" data-cid="547" data-userid="copyeditor 4729" data-username=" (Springer Books)" data-time="1462960437870" title="Deleted by (Springer Books) - 05/11/2016 3:23pm">d</span>-subunit containing extrasynaptic GABA receptors that mediate tonic inhibition (<span class="jrnlBibRef" data-type="ruleset" data-citation-string=" R57 R58 ">57,58</span>). Based on those findings and the extensive studies summarized by Reddy (<span class="jrnlBibRef" data-type="ruleset" data-citation-string=" R59 ">59</span>), Tan et al (<span class="jrnlBibRef" data-type="ruleset" data-citation-string=" R56 ">56</span>) proposed a possible therapeutic role for neurosteroids in PCDH19-FE. Ganaxolone (3a-hydroxy-3ß-methyl-5a-pregnan-20-one), which results from the addition of a 3ß-methyl group to allopregnanolone<span class="ins cts-2" data-cid="548" data-userid="copyeditor 4729" data-username=" (Springer Books)" data-time="1462960498494" title="Inserted by (Springer Books) - 05/11/2016 3:24pm">,</span> has undergone many trials over the years with varying success (<span class="jrnlBibRef" data-type="ruleset" data-citation-string=" R1 ">1</span>), but has now been selected for a targeted trial in patients with PCDH19-FE.</p><p class="jrnlSecPara" data-xpath="/div[2]/p[21]">If trials like this prove to be successful, <span class="ins cts-2" data-cid="549" data-userid="copyeditor 4729" data-username=" (Springer Books)" data-time="1462960582647" title="Inserted by (Springer Books) - 05/11/2016 3:26pm">it</span><span class="del cts-2" data-cid="551" data-userid="copyeditor 4729" data-username=" (Springer Books)" data-time="1462960583295" title="Deleted by (Springer Books) - 05/11/2016 3:26pm">such achievements</span> will reinforce the notion that the much touted ideas about the refractoriness of epilepsy in up to one-third of all patients is an artifact of the entry criteria used in most studies. Most clinical trial designs for regulatory approval are based only on seizure types and seizure counts; the underlying molecular pathologies are seldom used as considerations. This is a less acknowledged problem, whereas the limitations of existing animal models are frequently blamed for the lack of truly new solutions for patients with refractory epilepsy. Such a selection process serves commercial interests by offering a broad population in which a new drug might prove efficacious, <span class="authorQueryNode Author" id="1462960977281" rid="QRY_1462960977281" data-username=" (Springer Books)" data-time="05/11/2016 3:32pm">tanta<span class="del cts-2" data-cid="551" data-userid="copyeditor 4729" data-username=" (Springer Books)" data-time="1462960583295" title="Deleted by (Springer Books) - 05/11/2016 3:26pm">a</span>lizing </span>the developer with a large market. However, ignoring a more refined selection process based on etiology has condemned us to develop AEDs that will be predictably unhelpful to a sizable population of patients with chronic and refractory epilepsy.</p><p class="jrnlSecPara" data-xpath="/div[2]/p[22]">Another interesting facet to the neurosteroids story is the emergence of allopregnanolone being studied for <span class="ins cts-2" data-cid="572" data-userid="copyeditor 4729" data-username=" (Springer Books)" data-time="1462961048682" title="Inserted by (Springer Books) - 05/11/2016 3:34pm">the treatment of&nbsp;</span>super refractory status epilepticus (<span class="jrnlBibRef" data-type="ruleset" data-citation-string=" R60 ">60</span>). It has been suggested that the progressive internalization of synaptic GABA receptors is a mechanism underlying the pharmacoresistance in status epilepticus (<span class="jrnlBibRef" data-type="ruleset" data-citation-string=" R61 R62 ">61,62</span>). <span class="ins cts-2" data-cid="609" data-userid="copyeditor 4729" data-username=" (Springer Books)" data-time="1462961096018" title="Inserted by (Springer Books) - 05/11/2016 3:34pm">Because</span><span class="del cts-2" data-cid="596" data-userid="copyeditor 4729" data-username=" (Springer Books)" data-time="1462961075946" title="Deleted by (Springer Books) - 05/11/2016 3:34pm">Since</span> neuroactive steroids are potent positive allosteric modulators at the a6 and <span class="ins cts-2" data-cid="623" data-userid="copyeditor 4729" data-username=" (Springer Books)" data-time="1462961105403" title="Inserted by (Springer Books) - 05/11/2016 3:35pm">delta</span><span class="del cts-2" data-cid="630" data-userid="copyeditor 4729" data-username=" (Springer Books)" data-time="1462961107362" title="Deleted by (Springer Books) - 05/11/2016 3:35pm">d</span>-subunit containing extrasynaptic GABA receptors that mediate tonic inhibition, and because these receptors have not been observed to undergo internalization with ongoing seizure activity, treating super refractory status epilepticus with this class of compound<span class="ins cts-2" data-cid="631" data-userid="copyeditor 4729" data-username=" (Springer Books)" data-time="1462961134356" title="Inserted by (Springer Books) - 05/11/2016 3:35pm">s</span> would seem a very logical choice. Based on <span class="ins cts-2" data-cid="648" data-userid="copyeditor 4729" data-username=" (Springer Books)" data-time="1462961370561" title="Inserted by (Springer Books) - 05/11/2016 3:39pm">these observations</span><span class="del cts-2" data-cid="638" data-userid="copyeditor 4729" data-username=" (Springer Books)" data-time="1462961305865" title="Deleted by (Springer Books) - 05/11/2016 3:38pm">that concept</span>, and encouraging clinical reports of success in terminating status epilepticus after failure of numerous available medications (<span class="jrnlBibRef" data-type="ruleset" data-citation-string=" R63 R64 ">63,64</span>), a clinical trial of allopregnanolone for <span class="ins cts-2" data-cid="694" data-userid="copyeditor 4729" data-username=" (Springer Books)" data-time="1462961421691" title="Inserted by (Springer Books) - 05/11/2016 3:40pm">treatment of&nbsp;</span>super refractory status epilepticus is under way.</p><h1 class="jrnlHead1" align="center" data-xpath="/div[2]/h1[3]" bold="true" patternhead="true">CONCLUSIONS</h1><p class="jrnlSecPara" data-xpath="/div[2]/p[23]">In this chapter we have traced the evolution of pharmacological treatment of <span class="del cts-2" data-cid="707" data-userid="copyeditor 4729" data-username=" (Springer Books)" data-time="1462961461951" title="Deleted by (Springer Books) - 05/11/2016 3:41pm">the </span>epilepsies from the application of rational therapy (bromides) based on irrational beliefs (libido and hysteria) to the serendipitous discovery of phenobarbital. Improvements from this point on leveraged the synthetic prowess of medicinal chemistry and systematic screens using animal models. The diversity of animal models has increased, and molecular tinkering by medicinal chemists continues to yield important new compounds. We have now entered the post<span class="ins cts-2" data-cid="711" data-userid="copyeditor 4729" data-username=" (Springer Books)" data-time="1462961512484" title="Inserted by (Springer Books) - 05/11/2016 3:41pm">-</span><span class="del cts-2" data-cid="712" data-userid="copyeditor 4729" data-username=" (Springer Books)" data-time="1462961513044" title="Deleted by (Springer Books) - 05/11/2016 3:41pm"> </span>human genome project era, and new AED discovery is driven in many cases by advances in genetics, by reproducing the mutations in in vitro expression systems and in vivo transgenic animals. High<span class="ins cts-2" data-cid="713" data-userid="copyeditor 4729" data-username=" (Springer Books)" data-time="1462961561983" title="Inserted by (Springer Books) - 05/11/2016 3:42pm">-</span><span class="del cts-2" data-cid="714" data-userid="copyeditor 4729" data-username=" (Springer Books)" data-time="1462961562725" title="Deleted by (Springer Books) - 05/11/2016 3:42pm"> </span>throughput screening employing identified targets <span class="ins cts-2" data-cid="715" data-userid="copyeditor 4729" data-username=" (Springer Books)" data-time="1462961629610" title="Inserted by (Springer Books) - 05/11/2016 3:43pm">in</span><span class="del cts-2" data-cid="717" data-userid="copyeditor 4729" data-username=" (Springer Books)" data-time="1462961630398" title="Deleted by (Springer Books) - 05/11/2016 3:43pm">at</span> cellular or organ slices is also an evolving technology. Challenges posed by diversities in genetic background continue to thwart our assumptions of singular targets in many epilepsies when we approach human trials. These challenges will likely be amenable to solutions as we move from exome scanning to whole genome scanning<span class="del cts-2" data-cid="719" data-userid="copyeditor 4729" data-username=" (Springer Books)" data-time="1462961679393" title="Deleted by (Springer Books) - 05/11/2016 3:44pm">,</span> and develop critical bioinformatic solutions to tackle the influence of the interactions of targets with genetic background to produce the phenotype.</p></div><div class="back" data-xpath="/div[3]"><h1 class="jrnlRefHead" data-xpath="/div[3]/h1[1]" bold="true">REFERENCES</h1><p class="jrnlRefText noPMID" data-xpath="/div[3]/p[1]" seqid="1" id="R1" data-doi="10.1016/j.eplepsyres.2015.01.001" data-pmid="http://www.ncbi.nlm.nih.gov/pubmed/25769377" movetopanel="yes"><span class="RefSlNo">1. </span><span class="RefAuthor"><span class="RefSurName">Bialer</span> <span class="RefGivenName">M</span></span>, <span class="RefAuthor"><span class="RefSurName">Johannessen</span> <span class="RefGivenName">SI</span></span>, <span class="RefAuthor"><span class="RefSurName">Levy</span> <span class="RefGivenName">RH</span></span>, <span class="RefAuthor"><span class="RefSurName">Perucca</span> <span class="RefGivenName">E</span></span>, <span class="RefAuthor"><span class="RefSurName">Tomson</span> <span class="RefGivenName">T</span></span>, <span class="RefAuthor"><span class="RefSurName">White</span> <span class="RefGivenName">HS</span></span>. <span class="RefArticleTitle">Progress report on new antiepileptic drugs: a summary of the Twelfth Eilat Conference (EILAT XII)</span>. <span class="RefJournalTitle"><em>Epilepsy Res</em></span>. <span class="RefYear">2015</span>;<span class="RefVolume">111</span>:<span class="RefFPage">85</span>–<span class="RefLPage">141</span>.</p><p class="jrnlRefText noPMID" data-xpath="/div[3]/p[2]" seqid="2" id="R2" movetopanel="yes"><span class="RefSlNo">2. </span><span class="authorQueryNode Author" id="1462964864394" rid="QRY_1462964864394" data-username="Vijay (Springer Books)" data-time="05/11/2016 4:37pm"> </span><span class="RefArticleTitle"><span class="authorQueryNode Author" id="1462964864394" rid="QRY_1462964864394" data-username="Vijay (Springer Books)" data-time="05/11/2016 4:37pm">Meeting of the Royal Medical and Chirurgical Society of London, May 11, 1857</span></span><span class="authorQueryNode Author" id="1462964864394" rid="QRY_1462964864394" data-username="Vijay (Springer Books)" data-time="05/11/2016 4:37pm">.</span> <span class="RefJournalTitle"><i>Lancet</i></span>. <span class="RefYear">1857</span>:<span class="RefFPage">527</span>–<span class="RefLPage">528</span>.</p><p class="jrnlRefText noPMID" data-xpath="/div[3]/p[3]" seqid="3" id="R3"><span class="RefSlNo">3. </span><span class="RefAuthor"><span class="RefSurName">Hauptmann</span> <span class="RefGivenName">A</span></span>. <span class="RefArticleTitle">Luminal bei epilepsie</span>. <span class="RefJournalTitle"><i>Munch Med Wochenshr</i></span>. <span class="RefYear">1912</span>;<span class="RefVolume">59</span>:<span class="RefFPage">1907</span>–<span class="RefLPage">1909</span>.</p><p class="jrnlRefText noPMID" data-xpath="/div[3]/p[4]" seqid="4" id="R4"><span class="RefSlNo">4. </span><span class="RefAuthor"><span class="RefSurName">Merritt</span> <span class="RefGivenName">HH</span></span>, <span class="RefAuthor"><span class="RefSurName">Putnam</span> <span class="RefGivenName">TJ</span></span>. <span class="RefArticleTitle">Sodium diphenylhydantoinate in the treatment of convulsive disorders</span>. <span class="RefJournalTitle"><i>J Amer Med Assoc</i></span>. <span class="RefYear">1938</span>;<span class="RefVolume">111</span>:<span class="RefFPage">1608</span>–<span class="RefLPage">1073</span>.</p><p class="jrnlRefText noPMID" data-xpath="/div[3]/p[5]" seqid="5" id="R5"><span class="RefSlNo">5. </span><span class="RefAuthor"><span class="RefSurName">Merritt</span> <span class="RefGivenName">HH</span></span>, <span class="RefAuthor"><span class="RefSurName">Putnam</span> <span class="RefGivenName">TJ</span></span>. <span class="RefArticleTitle">A new series of anticonvulsant drugs tested by experiments on animals</span>. <span class="RefJournalTitle"><i>Arch Neurol Psychiatry</i></span>. <span class="RefYear">1938</span>;<span class="RefVolume">39</span>:<span class="RefFPage">1003</span>–<span class="RefLPage">1015</span>.</p><p class="jrnlRefText noPMID" data-xpath="/div[3]/p[6]" seqid="6" id="R6" movetopanel="yes"><span class="RefSlNo">6. </span><span class="RefAuthor"><span class="RefSurName">Richards</span> <span class="RefGivenName">RK</span></span>, <span class="RefAuthor"><span class="RefSurName">Everett</span> <span class="RefGivenName">GM</span></span>. <span class="RefArticleTitle">Tridione: a new anticonvulsant drug</span>. <span class="RefJournalTitle"><i>J Lab Clin Med</i></span>. <span class="RefYear">1946</span>;<span class="RefVolume">31</span>:<span class="RefFPage">1330</span>–<span class="RefLPage">1336</span>.</p><p class="jrnlRefText noPMID" data-xpath="/div[3]/p[7]" seqid="7" id="R7"><span class="RefSlNo">7. </span><span class="RefAuthor"><span class="RefSurName">Brodie</span> <span class="RefGivenName">MJ</span></span>. <span class="RefArticleTitle">Antiepileptic drug therapy the story so far</span>. <span class="RefJournalTitle"><i>Seizure</i></span>. <span class="RefYear">2010</span>;<span class="RefVolume">19</span>:<span class="RefFPage">650</span>–<span class="RefLPage">655</span>.</p><p class="jrnlRefText noPMID" data-xpath="/div[3]/p[8]" seqid="8" id="R8"><span class="RefSlNo">8. </span><span class="RefAuthor"><span class="RefSurName">Magiorkinis</span> <span class="RefGivenName">E</span></span>, <span class="RefAuthor"><span class="RefSurName">Diamantis</span> <span class="RefGivenName">A</span></span>, <span class="RefAuthor"><span class="RefSurName">Sidiropoulou</span> <span class="RefGivenName">K</span></span>, <span class="RefAuthor"><span class="RefSurName">Panteliadis</span> <span class="RefGivenName">C</span></span>. <span class="RefArticleTitle">Highlights in the history of epilepsy: the last 200 years</span>. <span class="RefJournalTitle"><i>Epilepsy Res Treat</i></span>. <span class="RefYear">2014</span>;<span class="RefVolume">2014</span>:<span class="RefFPage">582039</span>.</p><p class="jrnlRefText noPMID" data-xpath="/div[3]/p[9]" seqid="9" id="R9"><span class="RefSlNo">9. </span><span class="RefAuthor"><span class="RefSurName">Rho</span> <span class="RefGivenName">JM</span></span>, <span class="RefAuthor"><span class="RefSurName">Sankar</span> <span class="RefGivenName">R</span></span>. <span class="RefArticleTitle">The pharmacologic basis of antiepileptic drug action</span>. <span class="RefJournalTitle"><i>Epilepsia</i></span>. <span class="RefYear">1999</span>;<span class="RefVolume">40</span>:<span class="RefFPage">1471</span>–<span class="RefLPage">1483</span>.</p><p class="jrnlRefText noPMID" data-xpath="/div[3]/p[10]" seqid="10" id="R10" movetopanel="yes"><span class="RefSlNo">10. </span><span class="RefAuthor"><span class="RefSurName">Rho</span> <span class="RefGivenName">JM</span></span>, <span class="RefAuthor"><span class="RefSurName">Donevan</span> <span class="RefGivenName">SD</span></span>, <span class="RefAuthor"><span class="RefSurName">Rogawski</span> <span class="RefGivenName">MA</span></span>. <span class="RefArticleTitle">Mechanism of action of the anticonvulsant felbamate: opposing effects on N-methyl-D-aspartate and gamma-aminobutyric acid-a receptors</span>. <span class="RefJournalTitle"><i>Ann Neurol</i></span>. <span class="RefYear">1994</span>;<span class="RefVolume">35</span>:<span class="RefFPage">229</span>–<span class="RefLPage">234</span>.</p><p class="jrnlRefText noPMID" data-xpath="/div[3]/p[11]" seqid="11" id="R11" movetopanel="yes"><span class="RefSlNo">11. </span><span class="RefAuthor"><span class="RefSurName">Ceolin</span> <span class="RefGivenName">L</span></span>, <span class="RefAuthor"><span class="RefSurName">Bortolotto</span> <span class="RefGivenName">ZA</span></span>, <span class="RefAuthor"><span class="RefSurName">Bannister</span> <span class="RefGivenName">N</span></span>, <span class="RefAuthor"><span class="RefSurName">Collingridge</span> <span class="RefGivenName">GL</span></span>, <span class="RefAuthor"><span class="RefSurName">Lodge</span> <span class="RefGivenName">D</span></span>, <span class="RefAuthor"><span class="RefSurName">Volianskis</span> <span class="RefGivenName">A</span></span>. <span class="RefArticleTitle">A novel anti-epileptic agent, perampanel, selectively inhibits AMPA receptor-mediated synaptic transmission in the hippocampus</span>. <span class="RefJournalTitle"><i>Neurochem Int</i></span>. <span class="RefYear">2012</span>;<span class="RefVolume">61</span>:<span class="RefFPage">517</span>–<span class="RefLPage">522</span>.</p><p class="jrnlRefText noPMID" data-xpath="/div[3]/p[12]" seqid="12" id="R12" movetopanel="yes"><span class="RefSlNo">12. </span><span class="RefAuthor"><span class="RefSurName">Olsen</span> <span class="RefGivenName">RW</span></span>. <span class="RefChapterTitle">The y-aminobutyric acid/benzodiazepine/barbiturate receptor-chloride ion channel complex of mammalian brain</span>. <span class="RefComments">In</span>: <span class="RefEditor">Edelman&nbsp;GM</span>, <span class="RefEditor"> Gall&nbsp;WE</span>, <span class="RefEditor">Cowan&nbsp;WM</span>, <span class="RefComments">eds.</span> <span class="RefBookTitle"><i>Synaptic Function</i></span>. <span class="RefPublisherLoc">New York, NY</span>: <span class="RefPublisherName">John Wiley &amp; Sons</span>; <span class="RefYear">1987</span>:<span class="RefFPage">257</span>–<span class="RefLPage">271</span>.</p><p class="jrnlRefText noPMID" data-xpath="/div[3]/p[13]" seqid="13" id="R13"><span class="RefSlNo">13. </span><span class="RefAuthor"><span class="RefSurName">Gale</span> <span class="RefGivenName">K</span></span>, <span class="RefAuthor"><span class="RefSurName">Iadarola</span> <span class="RefGivenName">MJ</span></span>. <span class="RefArticleTitle">Seizure protection and increased nerve-terminal GABA: delayed effects of GABA transaminase inhibition</span>. <span class="RefJournalTitle"><i>Science</i></span>. <span class="RefYear">1980</span>;<span class="RefVolume">208</span>:<span class="RefFPage">288</span>–<span class="RefLPage">291</span>.</p><p class="jrnlRefText noPMID" data-xpath="/div[3]/p[14]" seqid="14" id="R14"><span class="RefSlNo">14. </span><span class="RefAuthor"><span class="RefSurName">Faingold</span> <span class="RefGivenName">CL</span></span>, <span class="RefAuthor"><span class="RefSurName">Randall</span> <span class="RefGivenName">ME</span></span>, <span class="RefAuthor"><span class="RefSurName">Anderson</span> <span class="RefGivenName">CA</span></span>. <span class="RefArticleTitle">Blockade of GABA uptake with tiagabine inhibits audiogenic seizures and reduces neuronal firing in the inferior colliculus of the genetically epilepsy-prone rat</span>. <span class="RefJournalTitle"><i>Exp Neurol</i></span>. <span class="RefYear">1994</span>;<span class="RefVolume">126</span>:<span class="RefFPage">225</span>–<span class="RefLPage">232</span>.</p><p class="jrnlRefText noPMID" data-xpath="/div[3]/p[15]" seqid="15" id="R15"><span class="RefSlNo">15. </span><span class="RefAuthor"><span class="RefSurName">van Hooft</span> <span class="RefGivenName">JA</span></span>, <span class="RefAuthor"><span class="RefSurName">Dougherty</span> <span class="RefGivenName">JJ</span></span>, <span class="RefAuthor"><span class="RefSurName">Endeman</span> <span class="RefGivenName">D</span></span>, <span class="RefAuthor"><span class="RefSurName">Nichols</span> <span class="RefGivenName">RA</span></span>, <span class="RefAuthor"><span class="RefSurName">Wadman</span> <span class="RefGivenName">WJ</span></span>. <span class="RefArticleTitle">Gabapentin inhibits presynaptic ca(2+) influx and synaptic transmission in rat hippocampus and neocortex</span>. <span class="RefJournalTitle"><i>Eur J Pharmacol</i></span>. <span class="RefYear">2002</span>;<span class="RefVolume">449</span>:<span class="RefFPage">221</span>–<span class="RefLPage">228</span>.</p><p class="jrnlRefText noPMID" id="R16" data-xpath="/div[3]/p[16]" seqid="R16"><span class="RefSlNo">16. </span><span class="RefAuthor"><span class="RefSurName">Lynch</span> <span class="RefGivenName">BA</span></span>, <span class="RefAuthor"><span class="RefSurName">Lambeng</span> <span class="RefGivenName">N</span></span>, <span class="RefAuthor"><span class="RefSurName">Nocka</span> <span class="RefGivenName">K</span></span>, <span class="RefEtal">et al</span>. <span class="RefArticleTitle">The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam</span>. <span class="RefJournalTitle"><i>Proc Natl Acad Sci U S A</i></span>. <span class="RefYear">2004</span>;<span class="RefVolume">101</span>:<span class="RefFPage">9861</span>–<span class="RefLPage">9866</span>.</p><p class="jrnlRefText noPMID" data-xpath="/div[3]/p[17]" seqid="18" id="R17" movetopanel="yes"><span class="RefSlNo">17. </span><span class="RefAuthor"><span class="RefSurName">Löscher</span> <span class="RefGivenName">W</span></span>. <span class="RefChapterTitle">Animal models of drug-refractory epilepsy</span>. <span class="RefComments">In</span>: <span class="RefEditor"><span class="RefSurName">Pitkänen</span> <span class="RefGivenName">A</span></span>, <span class="RefEditor"><span class="RefSurName">Schwartzkroin</span> <span class="RefGivenName">PA</span></span>, <span class="RefEditor"><span class="RefSurName">Moshé</span> <span class="RefGivenName">SL</span></span>, <span class="RefComments">eds.</span> <span class="RefBookTitle"><i>Models of Seizures and Epilepsy</i></span>. <span class="RefPublisherLoc">San Diego, CA</span>: <span class="RefPublisherName">Elsevier</span>; <span class="RefYear">2006</span>:<span class="RefFPage">551</span>–<span class="RefLPage">566</span>.</p><p class="jrnlRefText noPMID" data-xpath="/div[3]/p[18]" seqid="19" id="R18"><span class="RefSlNo">18. </span><span class="RefAuthor"><span class="RefSurName">Shandra</span> <span class="RefGivenName">AA</span></span>, <span class="RefAuthor"><span class="RefSurName">Mazarati</span> <span class="RefGivenName">AM</span></span>, <span class="RefAuthor"><span class="RefSurName">Godlevsky</span> <span class="RefGivenName">LS</span></span>, <span class="RefAuthor"><span class="RefSurName">Vastyanov</span> <span class="RefGivenName">RS</span></span>. <span class="RefArticleTitle">Chemical kindling: implications for antiepileptic drugs - sensitive and resistant epilepsy models</span>. <span class="RefJournalTitle"><i>Epilepsia</i></span>. <span class="RefYear">1996</span>;<span class="RefVolume">37</span>:<span class="RefFPage">269</span>–<span class="RefLPage">274</span>.</p><p class="jrnlRefText noPMID" data-xpath="/div[3]/p[19]" seqid="20" id="R19"><span class="RefSlNo">19. </span><span class="RefAuthor"><span class="RefSurName">Reissmüller</span> <span class="RefGivenName">E</span></span>, <span class="RefAuthor"><span class="RefSurName">Ebert</span> <span class="RefGivenName">U</span></span>, <span class="RefAuthor"><span class="RefSurName">Löscher</span> <span class="RefGivenName">W</span></span>. <span class="RefArticleTitle">Anticonvulsant efficacy of topiramate in phenytoin-resistant kindled rats</span>. <span class="RefJournalTitle"><i>Epilepsia</i></span>. <span class="RefYear">2000</span>;<span class="RefVolume">41</span>:<span class="RefFPage">372</span>–<span class="RefLPage">379</span>.</p><p class="jrnlRefText noPMID" data-xpath="/div[3]/p[20]" seqid="21" id="R20"><span class="RefSlNo">20. </span><span class="RefAuthor"><span class="RefSurName">Srivastava</span> <span class="RefGivenName">AK</span></span>, <span class="RefAuthor"><span class="RefSurName">White</span> <span class="RefGivenName">HS</span></span>. <span class="RefArticleTitle">Carbamazepine, but not valproate, displays pharmacoresistance in lamotrigine-resistant amygdala kindled rats</span>. <span class="RefJournalTitle"><i>Epilepsy Res</i></span>. <span class="RefYear">2013</span>;<span class="RefVolume">104</span>:<span class="RefFPage">26</span>–<span class="RefLPage">34</span>.</p><p class="jrnlRefText noPMID" data-xpath="/div[3]/p[21]" seqid="22" id="R21"><span class="RefSlNo">21. </span><span class="RefAuthor"><span class="RefSurName">Brandt</span> <span class="RefGivenName">C</span></span>, <span class="RefAuthor"><span class="RefSurName">Löscher</span> <span class="RefGivenName">W</span></span>. <span class="RefArticleTitle">Antiepileptic efficacy of lamotrigine in phenobarbital-resistant and -responsive epileptic rats: a pilot study</span>. <span class="RefJournalTitle"><i>Epilepsy Res</i></span>. <span class="RefYear">2014</span>;<span class="RefVolume">108</span>:<span class="RefFPage">1145</span>–<span class="RefLPage">1157</span>.</p><p class="jrnlRefText noPMID" data-xpath="/div[3]/p[22]" seqid="23" id="R22"><span class="RefSlNo">22. </span><span class="RefAuthor"><span class="RefSurName">Barton</span> <span class="RefGivenName">ME</span></span>, <span class="RefAuthor"><span class="RefSurName">Klein</span> <span class="RefGivenName">BD</span></span>, <span class="RefAuthor"><span class="RefSurName">Wolf</span> <span class="RefGivenName">HH</span></span>, <span class="RefAuthor"><span class="RefSurName">White</span> <span class="RefGivenName">HS</span></span>. <span class="RefArticleTitle">Pharmacological characterization of the 6 hz psychomotor seizure model of partial epilepsy</span>. <span class="RefJournalTitle"><i>Epilepsy Res</i></span>. <span class="RefYear">2001</span>;<span class="RefVolume">47</span>:<span class="RefFPage">217</span>–<span class="RefLPage">227</span>.</p><p class="jrnlRefText noPMID" data-xpath="/div[3]/p[23]" seqid="24" id="R23" movetopanel="yes"><span class="RefSlNo">23. </span><span class="RefAuthor"><span class="RefSurName">Crawford</span> <span class="RefGivenName">P</span></span>, <span class="RefAuthor"><span class="RefSurName">Chadwick</span> <span class="RefGivenName">D</span></span>. <span class="RefArticleTitle">A comparative study of progabide, valproate, and placebo as add-on therapy in patients with refractory epilepsy</span>. <span class="RefJournalTitle"><em>J Neurol Neurosurg Psychiatry</em></span>. <span class="RefYear">1986</span>;<span class="RefVolume">49</span>:<span class="RefFPage">1251</span>–<span class="RefLPage">1257</span>.</p><p class="jrnlRefText noPMID" data-xpath="/div[3]/p[24]" seqid="25" id="R24"><span class="RefSlNo">24. </span><span class="RefAuthor"><span class="RefSurName">Leppik</span> <span class="RefGivenName">IE</span></span>, <span class="RefAuthor"><span class="RefSurName">Dreifuss</span> <span class="RefGivenName">FE</span></span>, <span class="RefAuthor"><span class="RefSurName">Porter</span> <span class="RefGivenName">R</span></span>, <span class="RefEtal">et al</span>. <span class="RefArticleTitle">A controlled study of progabide in partial seizures: methodology and results</span>. <span class="RefJournalTitle"><i>Neurology</i></span>. <span class="RefYear">1987</span>;<span class="RefVolume">37</span>:<span class="RefFPage">963</span>–<span class="RefLPage">968</span>.</p><p class="jrnlRefText noPMID" data-xpath="/div[3]/p[25]" seqid="26" id="R25"><span class="RefSlNo">25. </span><span class="RefAuthor"><span class="RefSurName">Klitgaard</span> <span class="RefGivenName">H</span></span>, <span class="RefAuthor"><span class="RefSurName">Matagne</span> <span class="RefGivenName">A</span></span>, <span class="RefAuthor"><span class="RefSurName">Nicolas</span> <span class="RefGivenName">JM</span></span>, <span class="RefEtal">et al</span>. <span class="RefArticleTitle">Brivaracetam: rationale for discovery and preclinical profile of a selective SV2A ligand for epilepsy treatment</span>. <span class="RefJournalTitle"><i>Epilepsia</i></span>. <span class="RefYear">2016</span>;<span class="RefVolume">57</span>:<span class="RefFPage">538</span>–<span class="RefLPage">548</span>.</p><p class="jrnlRefText noPMID" data-xpath="/div[3]/p[26]" seqid="27" id="R26" movetopanel="yes"><span class="RefSlNo">26. </span><span class="RefAuthor"><span class="RefSurName">Pan</span> <span class="RefGivenName">Y</span></span>, <span class="RefAuthor"><span class="RefSurName">Qiu</span> <span class="RefGivenName">J</span></span>, <span class="RefAuthor"><span class="RefSurName">Silverman</span> <span class="RefGivenName">RB</span></span>. <span class="RefArticleTitle">Design, synthesis, and biological activity of a difluoro-substituted, conformationally rigid vigabatrin analogue as a potent gamma-aminobutyric acid aminotransferase inhibitor</span>. <span class="RefJournalTitle"><i>J Med Chem</i></span>. <span class="RefYear">2003</span>;<span class="RefVolume">46</span>:<span class="RefFPage">5292</span>.</p><p class="jrnlRefText noPMID" data-xpath="/div[3]/p[27]" seqid="28" id="R27" movetopanel="yes"><span class="RefSlNo">27. </span><span class="RefAuthor"><span class="RefSurName">Silverman</span> <span class="RefGivenName">RB</span></span>. <span class="RefArticleTitle">The 2011 E. B. hershberg award for important discoveries in medicinally active substances: (1S,3S)-3-amino-4-difluoromethylenyl-1-cyclopentanoic acid (CPP-115), a GABA aminotransferase inactivator and new treatment for drug addiction and infantile spasms</span>. <span class="RefJournalTitle"><i>J Med Chem</i></span>.<span class="RefVolume">2012</span>(<span class="RefIssue">55</span>):<span class="RefFPage">567</span>–<span class="RefLPage">575</span>.</p><p class="jrnlRefText noPMID" data-xpath="/div[3]/p[28]" seqid="29" id="R28"><span class="RefSlNo">28. </span><span class="RefAuthor"><span class="RefSurName">Briggs</span> <span class="RefGivenName">SW</span></span>, <span class="RefAuthor"><span class="RefSurName">Mowrey</span> <span class="RefGivenName">W</span></span>, <span class="RefAuthor"><span class="RefSurName">Hall</span> <span class="RefGivenName">CB</span></span>, <span class="RefAuthor"><span class="RefSurName">Galanopoulou</span> <span class="RefGivenName">AS</span></span>. <span class="RefArticleTitle">CPP-115, a vigabatrin analogue, decreases spasms in the multiple-hit rat model of infantile spasms</span>. <span class="RefJournalTitle"><i>Epilepsia</i></span>. <span class="RefYear">2014</span>;<span class="RefVolume">551</span>:<span class="RefFPage">94</span>–<span class="RefLPage">102</span>.</p><p class="jrnlRefText noPMID" data-xpath="/div[3]/p[29]" seqid="30" id="R29" movetopanel="yes"><span class="RefSlNo">29. </span><span class="RefAuthor"><span class="RefSurName">Bialer</span> <span class="RefGivenName">M</span></span>, <span class="RefAuthor"><span class="RefSurName">Johannessen</span> <span class="RefGivenName">SI</span></span>, <span class="RefAuthor"><span class="RefSurName">Levy</span> <span class="RefGivenName">RH</span></span>, <span class="RefAuthor"><span class="RefSurName">Perucca</span> <span class="RefGivenName">E</span></span>, <span class="RefAuthor"><span class="RefSurName">Tomson</span> <span class="RefGivenName">T</span></span>, <span class="RefAuthor"><span class="RefSurName">White</span> <span class="RefGivenName">HS</span></span>. <span class="RefArticleTitle">Progress report on new antiepileptic drugs: a summary of the Eleventh Eilat Conference (EILAT XI)</span>. <span class="RefJournalTitle"><span data-diff-rid="R134" class="del cts-1" title="Deleted by cross-ref - 2016/05/03 14:23 pm" data-cid="1462265587008" data-userid="cross-ref" data-username="cross-ref" data-time="1462265587000">Epilepsy Res</span><em><span class="ins cts-1" data-diff-rid="R134" title="Inserted by cross-ref - 2016/05/03 14:23 pm" data-cid="1462265587009" data-userid="cross-ref" data-username="cross-ref" data-time="1462265587000">Epilepsy Res</span></em></span>. <span class="RefYear">2013</span>;<span class="RefVolume">103</span>:<span class="RefFPage">2</span>–<span class="RefLPage">30</span>.</p><p class="jrnlRefText noPMID" data-xpath="/div[3]/p[30]" seqid="31" id="R30"><span class="RefSlNo">30. </span><span class="RefAuthor"><span class="RefSurName">Pressler</span> <span class="RefGivenName">RM</span></span>, <span class="RefAuthor"><span class="RefSurName">Boylan</span> <span class="RefGivenName">GB</span></span>, <span class="RefAuthor"><span class="RefSurName">Marlow</span> <span class="RefGivenName">N</span></span>, <span class="RefEtal">et al</span>. <span class="RefArticleTitle">Bumetanide for the treatment of seizures in newborn babies with hypoxic ischaemic encephalopathy (NEMO): an open-label, dose finding, and feasibility phase 1/2 trial</span>. <span class="RefJournalTitle"><i>Lancet Neurol</i></span>. <span class="RefYear">2015</span>;<span class="RefVolume">14</span>:<span class="RefFPage">469</span>–<span class="RefLPage">477</span>.</p><p class="jrnlRefText noPMID" data-xpath="/div[3]/p[31]" seqid="32" id="R31"><span class="RefSlNo">31. </span><span class="RefAuthor"><span class="RefSurName">Ravizza</span> <span class="RefGivenName">T</span></span>, <span class="RefAuthor"><span class="RefSurName">Noé</span> <span class="RefGivenName">F</span></span>, <span class="RefAuthor"><span class="RefSurName">Zardoni</span> <span class="RefGivenName">D</span></span>, <span class="RefAuthor"><span class="RefSurName">Vaghi</span> <span class="RefGivenName">V</span></span>, <span class="RefAuthor"><span class="RefSurName">Sifringer</span> <span class="RefGivenName">M</span></span>, <span class="RefAuthor"><span class="RefSurName">Vezzani</span> <span class="RefGivenName">A</span></span>. <span class="RefArticleTitle">Interleukin converting enzyme inhibition impairs kindling epileptogenesis in rats by blocking astrocytic il-1beta production</span>. <span class="RefJournalTitle"><i>Neurobiol Dis</i></span>. <span class="RefYear">2008</span>;<span class="RefVolume">31</span>:<span class="RefFPage">327</span>–<span class="RefLPage">333</span>.</p><p class="jrnlRefText noPMID" data-xpath="/div[3]/p[32]" seqid="33" id="R32"><span class="RefSlNo">32. </span><span class="RefAuthor"><span class="RefSurName">Maroso</span> <span class="RefGivenName">M</span></span>, <span class="RefAuthor"><span class="RefSurName">Balosso</span> <span class="RefGivenName">S</span></span>, <span class="RefAuthor"><span class="RefSurName">Ravizza</span> <span class="RefGivenName">T</span></span>, <span class="RefEtal">et al</span>. <span class="RefArticleTitle">Interleukin-1ß biosynthesis inhibition reduces acute seizures and drug resistant chronic epileptic activity in mice</span>. <span class="RefJournalTitle"><i>Neurotherapeutics</i></span>. <span class="RefYear">2011</span>;<span class="RefVolume">8</span>:<span class="RefFPage">304</span>–<span class="RefLPage">315</span>.</p><p class="jrnlRefText noPMID" data-xpath="/div[3]/p[33]" seqid="34" id="R33"><span class="RefSlNo">33. </span><span class="RefAuthor"><span class="RefSurName">Dzhala</span> <span class="RefGivenName">VI</span></span>, <span class="RefAuthor"><span class="RefSurName">Brumback</span> <span class="RefGivenName">AC</span></span>, <span class="RefAuthor"><span class="RefSurName">Staley</span> <span class="RefGivenName">KJ</span></span>. <span class="RefArticleTitle">Bumetanide enhances phenobarbital efficacy in a neonatal seizure model</span>. <span class="RefJournalTitle"><i>Ann Neurol</i></span>. <span class="RefYear">2008</span>;<span class="RefVolume">63</span>:<span class="RefFPage">222</span>–<span class="RefLPage">235</span>.</p><p class="jrnlRefText noPMID" data-xpath="/div[3]/p[34]" seqid="35" id="R34"><span class="RefSlNo">34. </span><span class="RefAuthor"><span class="RefSurName">Kahle</span> <span class="RefGivenName">KT</span></span>, <span class="RefAuthor"><span class="RefSurName">Barnett</span> <span class="RefGivenName">SM</span></span>, <span class="RefAuthor"><span class="RefSurName">Sassower</span> <span class="RefGivenName">KC</span></span>, <span class="RefAuthor"><span class="RefSurName">Staley</span> <span class="RefGivenName">KJ</span></span>. <span class="RefArticleTitle">Decreased seizure activity in a human neonate treated with bumetanide, an inhibitor of the na(+)-k(+)-2cl(-) cotransporter NKCC1</span>. <span class="RefJournalTitle"><i>J Child Neurol</i></span>. <span class="RefYear">2009</span>;<span class="RefVolume">24</span>:<span class="RefFPage">572</span>–<span class="RefLPage">576</span>.</p><p class="jrnlRefText noPMID" data-xpath="/div[3]/p[35]" seqid="36" id="R35"><span class="RefSlNo">35. </span><span class="RefAuthor"><span class="RefSurName">Milligan</span> <span class="RefGivenName">CJ</span></span>, <span class="RefAuthor"><span class="RefSurName">Li M</span> <span class="RefGivenName">GEV</span></span>, <span class="RefAuthor"><span class="RefSurName">Heron</span> <span class="RefGivenName">SE</span></span>, <span class="RefEtal">et al</span>. <span class="RefArticleTitle">KCNT1 gain of function in 2 epilepsy phenotypes is reversed by quinidine</span>. <span class="RefJournalTitle"><i>Ann Neurol</i></span>. <span class="RefYear">2014</span>;<span class="RefVolume">75</span>:<span class="RefFPage">581</span>–<span class="RefLPage">590</span>.</p><p class="jrnlRefText noPMID" data-xpath="/div[3]/p[36]" seqid="37" id="R36"><span class="RefSlNo">36. </span><span class="RefAuthor"><span class="RefSurName">Bearden</span> <span class="RefGivenName">D</span></span>, <span class="RefAuthor"><span class="RefSurName">Strong</span> <span class="RefGivenName">A</span></span>, <span class="RefAuthor"><span class="RefSurName">Ehnot</span> <span class="RefGivenName">J</span></span>, <span class="RefAuthor"><span class="RefSurName">Digiovine</span> <span class="RefGivenName">M</span></span>, <span class="RefAuthor"><span class="RefSurName">Dlugos</span> <span class="RefGivenName">D</span></span>, <span class="RefAuthor"><span class="RefSurName">Goldberg</span> <span class="RefGivenName">EM</span></span>. <span class="RefArticleTitle">Targeted treatment of migrating partial seizures of infancy with quinidine</span>. <span class="RefJournalTitle"><i>Ann Neurol</i></span>. <span class="RefYear">2014</span>;<span class="RefVolume">76</span>:<span class="RefFPage">457</span>–<span class="RefLPage">461</span>.</p><p class="jrnlRefText noPMID" data-xpath="/div[3]/p[37]" seqid="38" id="R37"><span class="RefSlNo">37. </span><span class="RefAuthor"><span class="RefSurName">Chong</span> <span class="RefGivenName">PF</span></span>, <span class="RefAuthor"><span class="RefSurName">Nakamura</span> <span class="RefGivenName">R</span></span>, <span class="RefAuthor"><span class="RefSurName">Saitsu</span> <span class="RefGivenName">H</span></span>, <span class="RefAuthor"><span class="RefSurName">Matsumoto</span> <span class="RefGivenName">N</span></span>, <span class="RefAuthor"><span class="RefSurName">Kira</span> <span class="RefGivenName">R</span></span>. <span class="RefArticleTitle">Ineffective quinidine therapy in early onset epileptic encephalopathy with KCNT1 mutation</span>. <span class="RefJournalTitle"><i>Ann Neurol</i></span>. <span class="RefYear">2016</span>;<span class="RefVolume">79</span>:<span class="RefFPage">502</span>–<span class="RefLPage">503</span>.</p><p class="jrnlRefText noPMID" data-xpath="/div[3]/p[38]" seqid="39" id="R38"><span class="RefSlNo">38. </span><span class="RefAuthor"><span class="RefSurName">Mikati</span> <span class="RefGivenName">MA</span></span>, <span class="RefAuthor"><span class="RefSurName">Jiang</span> <span class="RefGivenName">YH</span></span>, <span class="RefAuthor"><span class="RefSurName">Carboni</span> <span class="RefGivenName">M</span></span>, <span class="RefEtal">et al</span>. <span class="RefArticleTitle">Quinidine in the treatment of kcnt1-positive epilepsies</span>. <span class="RefJournalTitle"><i>Ann Neurol</i></span>. <span class="RefYear">2015</span>;<span class="RefVolume">78</span>:<span class="RefFPage">995</span>–<span class="RefLPage">999</span>.</p><p class="jrnlRefText noPMID" data-xpath="/div[3]/p[39]" seqid="40" id="R39" movetopanel="yes"><span class="RefSlNo">39. </span><span class="RefAuthor"><span class="RefSurName">Zeng</span> <span class="RefGivenName">LH</span></span>, <span class="RefAuthor"><span class="RefSurName">Xu</span> <span class="RefGivenName">L</span></span>, <span class="RefAuthor"><span class="RefSurName">Gutmann</span> <span class="RefGivenName">DH</span></span>, <span class="RefAuthor"><span class="RefSurName">Wong</span> <span class="RefGivenName">M</span></span>. <span class="RefArticleTitle">Rapamycin prevents epilepsy in a mouse model of tuberous sclerosis complex</span>. <span class="RefJournalTitle"><i>Ann Neurol</i></span>. <span class="RefYear">2008</span>;<span class="RefVolume">63</span>:<span class="RefFPage">444</span>–<span class="RefLPage">453</span>.</p><p class="jrnlRefText noPMID" data-xpath="/div[3]/p[40]" seqid="41" id="R40"><span class="RefSlNo">40. </span><span class="RefAuthor"><span class="RefSurName">Zeng</span> <span class="RefGivenName">LH</span></span>, <span class="RefAuthor"><span class="RefSurName">Rensing</span> <span class="RefGivenName">NR</span></span>, <span class="RefAuthor"><span class="RefSurName">Wong</span> <span class="RefGivenName">M</span></span>. <span class="RefArticleTitle">The mammalian target of rapamycin signaling pathway mediates epileptogenesis in a model of temporal lobe epilepsy</span>. <span class="RefJournalTitle"><i>J Neurosci</i></span>. <span class="RefYear">2009</span>;<span class="RefVolume">29</span>:<span class="RefFPage">6964</span>–<span class="RefLPage">6972</span>.</p><p class="jrnlRefText noPMID" data-xpath="/div[3]/p[41]" seqid="42" id="R41"><span class="RefSlNo">41. </span><span class="RefAuthor"><span class="RefSurName">Heng</span> <span class="RefGivenName">K</span></span>, <span class="RefAuthor"><span class="RefSurName">Haney</span> <span class="RefGivenName">MM</span></span>, <span class="RefAuthor"><span class="RefSurName">Buckmaster</span> <span class="RefGivenName">PS</span></span>. <span class="RefArticleTitle">High-dose rapamycin blocks mossy fiber sprouting but not seizures in a mouse model of temporal lobe epilepsy</span>. <span class="RefJournalTitle"><i>Epilepsia</i></span>. <span class="RefYear">2013</span>;<span class="RefVolume">54</span>:<span class="RefFPage">1535</span>–<span class="RefLPage">1541</span>.</p><p class="jrnlRefText noPMID" data-xpath="/div[3]/p[42]" seqid="43" id="R42"><span class="RefSlNo">42. </span><span class="RefAuthor"><span class="RefSurName">Krueger</span> <span class="RefGivenName">DA</span></span>, <span class="RefAuthor"><span class="RefSurName">Care</span> <span class="RefGivenName">MM</span></span>, <span class="RefAuthor"><span class="RefSurName">Holland</span> <span class="RefGivenName">K</span></span>, <span class="RefEtal">et al</span>. <span class="RefArticleTitle">Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis</span>. <span class="RefJournalTitle"><i>N Engl J Med</i></span>. <span class="RefYear">2010</span>;<span class="RefVolume">363</span>:<span class="RefFPage">1801</span>–<span class="RefLPage">1811</span>.</p><p class="jrnlRefText noPMID" data-xpath="/div[3]/p[43]" seqid="44" id="R43"><span class="RefSlNo">43. </span><span class="RefAuthor"><span class="RefSurName">Krueger</span> <span class="RefGivenName">DA</span></span>, <span class="RefAuthor"><span class="RefSurName">Wilfong</span> <span class="RefGivenName">AA</span></span>, <span class="RefAuthor"><span class="RefSurName">Holland-Bouley</span> <span class="RefGivenName">K</span></span>, <span class="RefEtal">et al</span>. <span class="RefArticleTitle">Everolimus treatment of refractory epilepsy in tuberous sclerosis complex</span>. <span class="RefJournalTitle"><i>Ann Neurol</i></span>. <span class="RefYear">2013</span>;<span class="RefVolume">74</span>:<span class="RefFPage">679</span>–<span class="RefLPage">687</span>.</p><p class="jrnlRefText noPMID" data-xpath="/div[3]/p[44]" seqid="45" id="R44"><span class="RefSlNo">44. </span><span class="RefAuthor"><span class="RefSurName">Cardamone</span> <span class="RefGivenName">M</span></span>, <span class="RefAuthor"><span class="RefSurName">Flanagan</span> <span class="RefGivenName">D</span></span>, <span class="RefAuthor"><span class="RefSurName">Mowat</span> <span class="RefGivenName">D</span></span>, <span class="RefAuthor"><span class="RefSurName">Kennedy</span> <span class="RefGivenName">SE</span></span>, <span class="RefAuthor"><span class="RefSurName">Chopra</span> <span class="RefGivenName">M</span></span>, <span class="RefAuthor"><span class="RefSurName">Lawson</span> <span class="RefGivenName">JA</span></span>. <span class="RefArticleTitle">Mammalian target of rapamycin inhibitors for intractable epilepsy and subependymal giant cell astrocytomas in tuberous sclerosis complex</span>. <span class="RefJournalTitle"><i>J Pediatr</i></span>. <span class="RefYear">2014</span>;<span class="RefVolume">164</span>:<span class="RefFPage">1195</span>–<span class="RefLPage">1200</span>.</p><p class="jrnlRefText" data-xpath="/div[3]/p[45]" seqid="46" id="R45"><span class="RefSlNo">45</span>. <span class="RefWebSite"><span class="authorQueryNode Author" id="1462964720462" rid="QRY_1462964720462" data-username="Vijay (Springer Books)" data-time="05/11/2016 4:35pm">https://clinicaltrials.gov/ct2/show/NCT01997255?term=everolimus&amp;rank=20</span></span></p><p class="jrnlRefText noPMID" data-xpath="/div[3]/p[46]" seqid="47" id="R46" movetopanel="yes"><span class="RefSlNo">46. </span><span class="RefAuthor"><span class="RefSurName">Wheless</span> <span class="RefGivenName">JW</span></span>. <span class="RefArticleTitle">History of the ketogenic diet</span>. <span class="RefJournalTitle"><i>Epilepsia</i></span>. <span class="RefYear">2008</span>;<span class="RefVolume">49</span>(<span class="RefIssue">Suppl 8</span>):<span class="RefFPage">3</span>–<span class="RefLPage">5</span>.</p><p class="jrnlRefText noPMID" data-xpath="/div[3]/p[47]" seqid="48" id="R47" movetopanel="yes"><span class="RefSlNo">47. </span><span class="RefAuthor"><span class="RefSurName">Rho</span> <span class="RefGivenName">JM</span></span>, <span class="RefAuthor"><span class="RefSurName">Sankar</span> <span class="RefGivenName">R</span></span>. <span class="RefArticleTitle">The ketogenic diet in a pill: is this possible?</span> <span class="RefJournalTitle"><i>Epilepsia</i></span>. <span class="RefYear">2008</span>;<span class="RefVolume">49</span>(<span class="RefIssue">Suppl 8</span>):<span class="RefFPage">127</span>–<span class="RefLPage">133</span>.</p><p class="jrnlRefText noPMID" data-xpath="/div[3]/p[48]" seqid="49" id="R48" movetopanel="yes"><span class="RefSlNo">48. </span><span class="RefAuthor"><span class="RefSurName">Rogawski</span> <span class="RefGivenName">MA</span></span>, <span class="RefAuthor"><span class="RefSurName">Löscher</span> <span class="RefGivenName">W</span></span>, <span class="RefAuthor"><span class="RefSurName">Rho</span> <span class="RefGivenName">JM</span></span>. <span class="RefChapterTitle">Mechanisms of Action of Antiseizure Drugs and the Ketogenic Diet</span>. <span class="RefComments">In</span>: <span class="RefEditor"><span class="RefSurName">Holmes</span> <span class="RefGivenName">GL</span></span>, <span class="RefEditor"><span class="RefSurName">Noebels</span> <span class="RefGivenName">JL</span></span>, <span class="RefComments">eds.</span> <span class="RefBookTitle"><em>Epilepsy: The Biology of a Spectrum Disorder</em></span>. <span class="RefPublisherLoc">Cold Spring, NY</span>: <span class="RefPublisherName">Harb Perspect Med</span>; <span class="RefYear">2016</span>:<span class="RefFPage">397</span>–<span class="RefLPage">424</span>.</p><p class="jrnlRefText noPMID" data-xpath="/div[3]/p[49]" seqid="50" id="R49" movetopanel="yes"><span class="RefSlNo">49. </span><span class="RefAuthor"><span class="RefSurName">Pfeifer</span> <span class="RefGivenName">HH</span></span>, <span class="RefAuthor"><span class="RefSurName">Thiele</span> <span class="RefGivenName">EA</span></span>. <span class="RefArticleTitle">Low-glycemic-index treatment: a liberalized ketogenic diet for treatment of intractable epilepsy</span>. <span class="RefJournalTitle"><i>Neurology</i></span>. <span class="RefYear">2005</span>;<span class="RefVolume">65</span>:<span class="RefFPage">1810</span>–<span class="RefLPage">1812</span>.</p><p class="jrnlRefText noPMID" data-xpath="/div[3]/p[50]" seqid="51" id="R50" movetopanel="yes"><span class="RefSlNo">50. </span><span class="RefAuthor"><span class="RefSurName">Ma</span> <span class="RefGivenName">W</span></span>, <span class="RefAuthor"><span class="RefSurName">Berg</span> <span class="RefGivenName">J</span></span>, <span class="RefAuthor"><span class="RefSurName">Yellen</span> <span class="RefGivenName">G</span></span>. <span class="RefArticleTitle">Ketogenic diet metabolites reduce firing in central neurons by opening K(ATP) channels</span>. <span class="RefJournalTitle"><em>J Neurosci</em></span>. <span class="RefYear">2007</span>;<span class="RefVolume">27</span>:<span class="RefFPage">3618</span>–<span class="RefLPage">3625</span>.</p><p class="jrnlRefText noPMID" data-xpath="/div[3]/p[51]" seqid="52" id="R51"><span class="RefSlNo">51. </span><span class="RefAuthor"><span class="RefSurName">Garriga-Canut</span> <span class="RefGivenName">M</span></span>, <span class="RefAuthor"><span class="RefSurName">Schoenike</span> <span class="RefGivenName">B</span></span>, <span class="RefAuthor"><span class="RefSurName">Qazi</span> <span class="RefGivenName">R</span></span>, <span class="RefEtal">et al</span>. <span class="RefArticleTitle">2-deoxy-d-glucose reduces epilepsy progression by nrsf-ctbp-dependent metabolic regulation of chromatin structure</span>. <span class="RefJournalTitle"><i>Nat Neurosci</i></span>. <span class="RefYear">2006</span>;<span class="RefVolume">9</span>:<span class="RefFPage">1382</span>–<span class="RefLPage">1387</span>.</p><p class="jrnlRefText noPMID" data-xpath="/div[3]/p[52]" seqid="53" id="R52" movetopanel="yes"><span class="RefSlNo">52. </span><span class="RefAuthor"><span class="RefSurName">Minor</span> <span class="RefGivenName">RK</span></span>, <span class="RefAuthor"><span class="RefSurName">Smith</span> <span class="RefGivenName">DL</span></span>, <span class="RefAuthor"><span class="RefSurName">Sossang</span> <span class="RefGivenName">AM</span></span>, <span class="RefEtal">et al</span>. <span class="RefArticleTitle">Chronic ingestion of 2-deoxy-d-glucose induces cardiac vacuolization and increases mortality in rats</span>. <span class="RefJournalTitle"><i>Toxicol Appl Pharmacol</i></span>. <span class="RefYear">2010</span>;<span class="RefVolume">243</span>:<span class="RefFPage">332</span>–<span class="RefLPage">339</span>.</p><p class="jrnlRefText noPMID" data-xpath="/div[3]/p[53]" seqid="54" id="R53"><span class="RefSlNo">53. </span><span class="RefAuthor"><span class="RefSurName">Stein</span> <span class="RefGivenName">M</span></span>, <span class="RefAuthor"><span class="RefSurName">Lin</span> <span class="RefGivenName">H</span></span>, <span class="RefAuthor"><span class="RefSurName">Jeyamohan</span> <span class="RefGivenName">C</span></span>, <span class="RefEtal">et al</span>. <span class="RefArticleTitle">Targeting tumor metabolism with 2-deoxyglucose in patients with castrate-resistant prostate cancer and advanced malignancies</span>. <span class="RefJournalTitle"><i>Prostate</i></span>. <span class="RefYear">2010</span>;<span class="RefVolume">2010</span>(<span class="RefIssue">70</span>):<span class="RefFPage">1388</span>–<span class="RefLPage">1394</span>.</p><p class="jrnlRefText noPMID" data-xpath="/div[3]/p[54]" seqid="55" id="R54" movetopanel="yes"><span class="RefSlNo">54. </span><span class="RefAuthor"><span class="RefSurName">Terse</span> <span class="RefGivenName">PS</span></span>, <span class="RefAuthor"><span class="RefSurName">Joshi</span> <span class="RefGivenName">PS</span></span>, <span class="RefAuthor"><span class="RefSurName">Bordelon</span> <span class="RefGivenName">NR</span></span>, <span class="RefEtal">et al</span>. <span class="RefArticleTitle">2-deoxy-d-glucose (2-dg)-induced cardiac toxicity in rat: nt-probnp and BNP as potential early cardiac safety biomarkers</span>. <span class="RefJournalTitle"><i>Int J Toxicol</i></span>. <span class="RefYear">2016</span><span class="del" data-userid="5752" data-username="Bala (Springer Books)">;</span>.</p><p class="jrnlRefText noPMID" data-xpath="/div[3]/p[55]" seqid="56" id="R55"><span class="RefSlNo">55. </span><span class="RefAuthor"><span class="RefSurName">Dibbens</span> <span class="RefGivenName">LM</span></span>, <span class="RefAuthor"><span class="RefSurName">Tarpey</span> <span class="RefGivenName">PS</span></span>, <span class="RefAuthor"><span class="RefSurName">Hynes</span> <span class="RefGivenName">K</span></span>, <span class="RefEtal">et al</span>. <span class="RefArticleTitle">X-linked protocadherin 19 mutations cause female-limited epilepsy and cognitive impairment</span>. <span class="RefJournalTitle"><i>Nat Genet</i></span>. <span class="RefYear">2008</span>;<span class="RefVolume">40</span>:<span class="RefFPage">776</span>–<span class="RefLPage">781</span>.</p><p class="jrnlRefText noPMID" data-xpath="/div[3]/p[56]" seqid="57" id="R56"><span class="RefSlNo">56. </span><span class="RefAuthor"><span class="RefSurName">Tan</span> <span class="RefGivenName">C</span></span>, <span class="RefAuthor"><span class="RefSurName">Shard</span> <span class="RefGivenName">C</span></span>, <span class="RefAuthor"><span class="RefSurName">Ranieri</span> <span class="RefGivenName">E</span></span>, <span class="RefEtal">et al</span>. <span class="RefArticleTitle">Mutations of protocadherin 19 in female epilepsy (PCDH19-FE) lead to allopregnanolone deficiency</span>. <span class="RefJournalTitle"><i>Hum Mol Genet</i></span>. <span class="RefYear">2015</span>;<span class="RefVolume">24</span>:<span class="RefFPage">5250</span>–<span class="RefLPage">5259</span>.</p><p class="jrnlRefText noPMID" data-xpath="/div[3]/p[57]" seqid="58" id="R57"><span class="RefSlNo">57. </span><span class="RefAuthor"><span class="RefSurName">Belelli</span> <span class="RefGivenName">D</span></span>, <span class="RefAuthor"><span class="RefSurName">Bolger</span> <span class="RefGivenName">MB</span></span>, <span class="RefAuthor"><span class="RefSurName">Gee</span> <span class="RefGivenName">KW</span></span>. <span class="RefArticleTitle">Anticonvulsant profile of the progesterone metabolite 5a-pregnan-3a-ol-20-one</span>. <span class="RefJournalTitle"><i>Eur J Pharmacol</i></span>. <span class="RefYear">1989</span>;<span class="RefVolume">166</span>:<span class="RefFPage">325</span>–<span class="RefLPage">329</span>.</p><p class="jrnlRefText noPMID" data-xpath="/div[3]/p[58]" seqid="59" id="R58"><span class="RefSlNo">58. </span><span class="RefAuthor"><span class="RefSurName">Stell</span> <span class="RefGivenName">BM</span></span>, <span class="RefAuthor"><span class="RefSurName">Brickley</span> <span class="RefGivenName">SG</span></span>, <span class="RefAuthor"><span class="RefSurName">Tang</span> <span class="RefGivenName">CY</span></span>, <span class="RefAuthor"><span class="RefSurName">Farrant</span> <span class="RefGivenName">M</span></span>, <span class="RefAuthor"><span class="RefSurName">Mody</span> <span class="RefGivenName">I</span></span>. <span class="RefArticleTitle">Neuroactive steroids reduce neuronal excitability by selectively enhancing tonic inhibition mediated by d subunit-containing GABAA receptors</span>. <span class="RefJournalTitle"><i>Proc Natl Acad Sci USA</i></span>. <span class="RefYear">2003</span>;<span class="RefVolume">100</span>:<span class="RefFPage">14439</span>–<span class="RefLPage">14444</span>.</p><p class="jrnlRefText noPMID" data-xpath="/div[3]/p[59]" seqid="60" id="R59" movetopanel="yes"><span class="RefSlNo">59. </span><span class="RefAuthor"><span class="RefSurName">Reddy</span> <span class="RefGivenName">DS</span></span>. <span class="RefArticleTitle">Neurosteroids: endogenous role in the human brain and therapeutic potentials</span>. <span class="RefJournalTitle"><i>Prog Brain Res</i></span>. <span class="RefYear">2010</span>;<span class="RefVolume">186</span>:<span class="RefFPage">113</span>–<span class="RefLPage">137</span>.</p><p class="jrnlRefText noPMID" data-xpath="/div[3]/p[60]" seqid="61" id="R60" movetopanel="yes"><span class="RefSlNo">60. </span><span class="RefAuthor"><span class="RefSurName">Rogawski</span> <span class="RefGivenName">MA</span></span>, <span class="RefAuthor"><span class="RefSurName">Loya</span> <span class="RefGivenName">CM</span></span>, <span class="RefAuthor"><span class="RefSurName">Reddy</span> <span class="RefGivenName">K</span></span>, <span class="RefAuthor"><span class="RefSurName">Zolkowska</span> <span class="RefGivenName">D</span></span>, <span class="RefAuthor"><span class="RefSurName">Lossin</span> <span class="RefGivenName">C</span></span>. <span class="RefArticleTitle">Neuroactive steroids for the treatment of status epilepticus</span>. <span class="RefJournalTitle"><i>Epilepsia</i></span>. <span class="RefYear">2013</span>;<span class="RefVolume">54</span>(<span class="RefIssue">Suppl 6</span>):<span class="RefFPage">93</span>–<span class="RefLPage">98</span>.</p><p class="jrnlRefText noPMID" data-xpath="/div[3]/p[61]" seqid="62" id="R61"><span class="RefSlNo">61. </span><span class="RefAuthor"><span class="RefSurName">Naylor</span> <span class="RefGivenName">DE</span></span>, <span class="RefAuthor"><span class="RefSurName">Liu</span> <span class="RefGivenName">H</span></span>, <span class="RefAuthor"><span class="RefSurName">Wasterlain</span> <span class="RefGivenName">CG</span></span>. <span class="RefArticleTitle">Trafficking of GABA(A) receptors, loss of inhibition, and a mechanism for pharmacoresistance in status epilepticus</span>. <span class="RefJournalTitle"><i>J Neurosci</i></span>. <span class="RefYear">2005</span>;<span class="RefVolume">25</span>:<span class="RefFPage">7724</span>–<span class="RefLPage">7733</span>.</p><p class="jrnlRefText noPMID" data-xpath="/div[3]/p[62]" seqid="63" id="R62"><span class="RefSlNo">62. </span><span class="RefAuthor"><span class="RefSurName">Goodkin</span> <span class="RefGivenName">HP</span></span>, <span class="RefAuthor"><span class="RefSurName">Joshi</span> <span class="RefGivenName">S</span></span>, <span class="RefAuthor"><span class="RefSurName">Mtchedlishvili</span> <span class="RefGivenName">Z</span></span>, <span class="RefAuthor"><span class="RefSurName">Brar</span> <span class="RefGivenName">J</span></span>, <span class="RefAuthor"><span class="RefSurName">Kapur</span> <span class="RefGivenName">J</span></span>. <span class="RefArticleTitle">Subunit-specific trafficking of GABA(A) receptors during status epilepticus</span>. <span class="RefJournalTitle"><i>J Neurosci</i></span>. <span class="RefYear">2008</span>;<span class="RefVolume">28</span>:<span class="RefFPage">2527</span>–<span class="RefLPage">2538</span>.</p><p class="jrnlRefText noPMID" data-xpath="/div[3]/p[63]" seqid="64" id="R63" movetopanel="yes"><span class="RefSlNo">63. </span><span class="RefAuthor"><span class="RefSurName">Vaitkevicius</span> <span class="RefGivenName">H</span></span>, <span class="RefAuthor"><span class="RefSurName">Ng</span> <span class="RefGivenName">M</span></span>, <span class="RefAuthor"><span class="RefSurName">Moura</span> <span class="RefGivenName">L</span></span>, <span class="RefEtal">et al</span>. <span class="RefArticleTitle">Successful allopregnanolone treatment of new onset refractory status epilepticus (NORSE) syndrome: first in man experience</span>. <span class="RefJournalTitle"><i>Epilepsia</i></span>. <span class="RefYear">2013</span>;<span class="RefVolume">54</span>(<span class="RefIssue">Suppl 6</span>):<span class="RefFPage">106</span>–<span class="RefLPage">124</span>.</p><p class="jrnlRefText noPMID" data-xpath="/div[3]/p[64]" seqid="65" id="R64"><span class="RefSlNo">64. </span><span class="RefAuthor"><span class="RefSurName">Broomall</span> <span class="RefGivenName">E</span></span>, <span class="RefAuthor"><span class="RefSurName">Natale</span> <span class="RefGivenName">JE</span></span>, <span class="RefAuthor"><span class="RefSurName">Grimason</span> <span class="RefGivenName">M</span></span>, <span class="RefEtal">et al</span>. <span class="RefArticleTitle">Pediatric super-refractory status epilepticus treated with allopregnanolone</span>. <span class="RefJournalTitle"><i>Ann Neurol</i></span>. <span class="RefYear">2014</span>;<span class="RefVolume">76</span>:<span class="RefFPage">911</span>–<span class="RefLPage">915</span>.</p></div></div><div id="queryDivNode" class="queryDivNode"><div class="row panel authorQuery panel-info" id="QRY_1462789990279"><div class="col-xs-3 details panel-heading"><span class="query-raised-by"><span class="change-owner-name row"><span class="glyphicon glyphicon-user"></span> <span class="queriedTo">Author</span> Query: <span class="queriedBy"> (Springer Books)</span></span><span class="changeMadeOn row"><span class="glyphicon glyphicon-time"></span> <span class="queriedOn">05/09/16 4:03pm</span></span></span></div><div class="col-xs-9 row changes panel-body"><div class="col-xs-10"><span class="queryBlock"><span class="queryText">AU: "attributed to" instead?</span></span></div><div class="col-xs-2 queryControl"><span class="fa fa-edit userEditQuery pull-right">&nbsp;</span><span class="fa fa-trash-o userDeleteQuery pull-right">&nbsp;</span></div></div></div><div class="row panel authorQuery panel-info" id="QRY_1462790597935"><div class="col-xs-3 details panel-heading"><span class="query-raised-by"><span class="change-owner-name row"><span class="glyphicon glyphicon-user"></span> <span class="queriedTo">Author</span> Query: <span class="queriedBy"> (Springer Books)</span></span><span class="changeMadeOn row"><span class="glyphicon glyphicon-time"></span> <span class="queriedOn">05/09/16 4:13pm</span></span></span></div><div class="col-xs-9 row changes panel-body"><div class="col-xs-10"><span class="queryBlock"><span class="queryText">AU: Edits to the caption for Figure 69.1 okay?</span></span></div><div class="col-xs-2 queryControl"><span class="fa fa-edit userEditQuery pull-right">&nbsp;</span><span class="fa fa-trash-o userDeleteQuery pull-right">&nbsp;</span></div></div></div><div class="row panel authorQuery panel-danger" id="QRY_1462791262671"><div class="col-xs-3 details panel-heading"><span class="query-raised-by"><span class="change-owner-name row"><span class="glyphicon glyphicon-user"></span> <span class="queriedTo">Typesetter</span> Query: <span class="queriedBy"> (Springer Books)</span></span><span class="changeMadeOn row"><span class="glyphicon glyphicon-time"></span> <span class="queriedOn">05/09/16 4:24pm</span></span></span></div><div class="col-xs-9 row changes panel-body"><div class="col-xs-10"><span class="queryBlock"><span class="queryText">COMP: "d" should be in small caps.</span></span></div><div class="col-xs-2 queryControl"><span class="fa fa-edit userEditQuery pull-right">&nbsp;</span><span class="fa fa-trash-o userDeleteQuery pull-right">&nbsp;</span></div></div></div><div class="row panel authorQuery panel-info" id="QRY_1462791741002"><div class="col-xs-3 details panel-heading"><span class="query-raised-by"><span class="change-owner-name row"><span class="glyphicon glyphicon-user"></span> <span class="queriedTo">Author</span> Query: <span class="queriedBy"> (Springer Books)</span></span><span class="changeMadeOn row"><span class="glyphicon glyphicon-time"></span> <span class="queriedOn">05/09/16 4:32pm</span></span></span></div><div class="col-xs-9 row changes panel-body"><div class="col-xs-10"><span class="queryBlock"><span class="queryText">AU: Edits okay?</span></span></div><div class="col-xs-2 queryControl"><span class="fa fa-edit userEditQuery pull-right">&nbsp;</span><span class="fa fa-trash-o userDeleteQuery pull-right">&nbsp;</span></div></div></div><div class="row panel authorQuery panel-info" id="QRY_1462795403043"><div class="col-xs-3 details panel-heading"><span class="query-raised-by"><span class="change-owner-name row"><span class="glyphicon glyphicon-user"></span> <span class="queriedTo">Author</span> Query: <span class="queriedBy"> (Springer Books)</span></span><span class="changeMadeOn row"><span class="glyphicon glyphicon-time"></span> <span class="queriedOn">05/09/16 5:33pm</span></span></span></div><div class="col-xs-9 row changes panel-body"><div class="col-xs-10"><span class="queryBlock"><span class="queryText">AU:&nbsp;"a<sub>2</sub>d" instead?</span></span></div><div class="col-xs-2 queryControl"><span class="fa fa-edit userEditQuery pull-right">&nbsp;</span><span class="fa fa-trash-o userDeleteQuery pull-right">&nbsp;</span></div></div></div><div class="row panel authorQuery panel-info" id="QRY_1462877611122"><div class="col-xs-3 details panel-heading"><span class="query-raised-by"><span class="change-owner-name row"><span class="glyphicon glyphicon-user"></span> <span class="queriedTo">Author</span> Query: <span class="queriedBy"> (Springer Books)</span></span><span class="changeMadeOn row"><span class="glyphicon glyphicon-time"></span> <span class="queriedOn">05/10/16 4:23pm</span></span></span></div><div class="col-xs-9 row changes panel-body"><div class="col-xs-10"><span class="queryBlock"><span class="queryText">AU: "The feasibility and economics of the application of this approach" instead?</span></span></div><div class="col-xs-2 queryControl"><span class="fa fa-edit userEditQuery pull-right">&nbsp;</span><span class="fa fa-trash-o userDeleteQuery pull-right">&nbsp;</span></div></div></div><div class="row panel authorQuery panel-info" id="QRY_1462878780467"><div class="col-xs-3 details panel-heading"><span class="query-raised-by"><span class="change-owner-name row"><span class="glyphicon glyphicon-user"></span> <span class="queriedTo">Author</span> Query: <span class="queriedBy"> (Springer Books)</span></span><span class="changeMadeOn row"><span class="glyphicon glyphicon-time"></span> <span class="queriedOn">05/10/16 4:43pm</span></span></span></div><div class="col-xs-9 row changes panel-body"><div class="col-xs-10"><span class="queryBlock"><span class="queryText">AU: Please rephrase this text as its meaning is not clear.</span></span></div><div class="col-xs-2 queryControl"><span class="fa fa-edit userEditQuery pull-right">&nbsp;</span><span class="fa fa-trash-o userDeleteQuery pull-right">&nbsp;</span></div></div></div><div class="row panel authorQuery panel-info" id="QRY_1462881745485"><div class="col-xs-3 details panel-heading"><span class="query-raised-by"><span class="change-owner-name row"><span class="glyphicon glyphicon-user"></span> <span class="queriedTo">Author</span> Query: <span class="queriedBy"> (Springer Books)</span></span><span class="changeMadeOn row"><span class="glyphicon glyphicon-time"></span> <span class="queriedOn">05/11/16 3:16pm</span></span></span></div><div class="col-xs-9 row changes panel-body"><div class="col-xs-10"><span class="queryBlock"><span class="queryText">AU: Please define the abbreviations KCNT,&nbsp;NKCC, SLACK, VX if needed in the footnote to Table 69.1.</span></span></div><div class="col-xs-2 queryControl"><span class="fa fa-edit userEditQuery pull-right">&nbsp;</span><span class="fa fa-trash-o userDeleteQuery pull-right">&nbsp;</span></div></div></div><div class="row panel authorQuery panel-info" id="QRY_1462948009497"><div class="col-xs-3 details panel-heading"><span class="query-raised-by"><span class="change-owner-name row"><span class="glyphicon glyphicon-user"></span> <span class="queriedTo">Author</span> Query: <span class="queriedBy"> (Springer Books)</span></span><span class="changeMadeOn row"><span class="glyphicon glyphicon-time"></span> <span class="queriedOn">05/11/16 11:56am</span></span></span></div><div class="col-xs-9 row changes panel-body"><div class="col-xs-10"><span class="queryBlock"><span class="queryText">AU: "SLACK" instead, to match the format in Table 69.1?</span></span></div><div class="col-xs-2 queryControl"><span class="fa fa-edit userEditQuery pull-right">&nbsp;</span><span class="fa fa-trash-o userDeleteQuery pull-right">&nbsp;</span></div></div></div><div class="row panel authorQuery panel-danger" id="QRY_1462959219647"><div class="col-xs-3 details panel-heading"><span class="query-raised-by"><span class="change-owner-name row"><span class="glyphicon glyphicon-user"></span> <span class="queriedTo">Typesetter</span> Query: <span class="queriedBy"> (Springer Books)</span></span><span class="changeMadeOn row"><span class="glyphicon glyphicon-time"></span> <span class="queriedOn">05/11/16 3:03pm</span></span></span></div><div class="col-xs-9 row changes panel-body"><div class="col-xs-10"><span class="queryBlock"><span class="queryText">COMP: "d" should be in small caps.</span></span></div><div class="col-xs-2 queryControl"><span class="fa fa-edit userEditQuery pull-right">&nbsp;</span><span class="fa fa-trash-o userDeleteQuery pull-right">&nbsp;</span></div></div></div><div class="row panel authorQuery panel-danger" id="QRY_1462959263508"><div class="col-xs-3 details panel-heading"><span class="query-raised-by"><span class="change-owner-name row"><span class="glyphicon glyphicon-user"></span> <span class="queriedTo">Typesetter</span> Query: <span class="queriedBy"> (Springer Books)</span></span><span class="changeMadeOn row"><span class="glyphicon glyphicon-time"></span> <span class="queriedOn">05/11/16 3:04pm</span></span></span></div><div class="col-xs-9 row changes panel-body"><div class="col-xs-10"><span class="queryBlock"><span class="queryText">COMP: "d" should be in small caps.</span></span></div><div class="col-xs-2 queryControl"><span class="fa fa-edit userEditQuery pull-right">&nbsp;</span><span class="fa fa-trash-o userDeleteQuery pull-right">&nbsp;</span></div></div></div><div class="row panel authorQuery panel-info" id="QRY_1462960977281"><div class="col-xs-3 details panel-heading"><span class="query-raised-by"><span class="change-owner-name row"><span class="glyphicon glyphicon-user"></span> <span class="queriedTo">Author</span> Query: <span class="queriedBy"> (Springer Books)</span></span><span class="changeMadeOn row"><span class="glyphicon glyphicon-time"></span> <span class="queriedOn">05/11/16 3:33pm</span></span></span></div><div class="col-xs-9 row changes panel-body"><div class="col-xs-10"><span class="queryBlock"><span class="queryText">AU: "tempting" instead?</span></span></div><div class="col-xs-2 queryControl"><span class="fa fa-edit userEditQuery pull-right">&nbsp;</span><span class="fa fa-trash-o userDeleteQuery pull-right">&nbsp;</span></div></div></div><div class="row panel authorQuery panel-info" id="QRY_1462964720462"><div class="col-xs-3 details panel-heading"><span class="query-raised-by"><span class="change-owner-name row"><span class="glyphicon glyphicon-user"></span> <span class="queriedTo">Author</span> Query: <span class="queriedBy">Vijay (Springer Books)</span></span><span class="changeMadeOn row"><span class="glyphicon glyphicon-time"></span> <span class="queriedOn">05/11/16 4:35pm</span></span></span></div><div class="col-xs-9 row changes panel-body"><div class="col-xs-10"><span class="queryBlock"><span class="queryText">AU: PLease provide complete details for this reference.</span></span></div><div class="col-xs-2 queryControl"><span class="fa fa-edit userEditQuery pull-right">&nbsp;</span><span class="fa fa-trash-o userDeleteQuery pull-right">&nbsp;</span></div></div></div><div class="row panel authorQuery panel-info" id="QRY_1462964864394"><div class="col-xs-3 details panel-heading"><span class="query-raised-by"><span class="change-owner-name row"><span class="glyphicon glyphicon-user"></span> <span class="queriedTo">Author</span> Query: <span class="queriedBy">Vijay (Springer Books)</span></span><span class="changeMadeOn row"><span class="glyphicon glyphicon-time"></span> <span class="queriedOn">05/11/16 4:37pm</span></span></span></div><div class="col-xs-9 row changes panel-body"><div class="col-xs-10"><span class="queryBlock"><span class="queryText">AU: Please provide Author(s) name for this reference.</span></span></div><div class="col-xs-2 queryControl"><span class="fa fa-edit userEditQuery pull-right">&nbsp;</span><span class="fa fa-trash-o userDeleteQuery pull-right">&nbsp;</span></div></div></div></div>